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Paediatric poisoning is a common presentation to emergency departments worldwide. There is a 5 
paucity of data on the role of liquid chromatography-tandem mass spectrometry (LC-MS/MS), in 6 
the management of paediatric poisoning in low-and middle-income countries (LMICs). In high-7 




The study describes the prevalence of liquid chromatography-tandem mass spectrometry 12 





Children admitted with suspected poisoning between 1 January 2017 and 31 December 2017, 18 
were recruited. All patients had a urine and/or blood sample sent for LC-MS/MS toxicology. Data 19 
collected included demographic data, clinical features, investigations, management, outcome and 20 
social interventions. 21 
  22 
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Results 23 
  24 
152 children, with median age of 39 (IQR 25 -61) months were enrolled of which 128 (84%) were 25 
poisoning cases. Of the 128 poisoning cases, 88 (69%) presented with a history of ingesting a 26 
known substance, 16(12%) an unknown substance and 24(19%) were cases of occult poisoning. 27 
LC-MS/MS was able to identify a substance in 92% of the cases of occult poisoning. In those who 28 
had presented with a seemingly known substance, LC-MS/MS found a different substance in 15 29 
cases. LC-MS/MS was also able to detect multiple drugs in 40 patients. Of the poisoning cases, six 30 
(5%) cases were attempted homicide cases and 5 (4%) cases were attempted suicide cases. No 31 
children died.  Individualized social interventions were instituted in poisoning cases. Emergency 32 
placement safety reasons was required in 6 children. 33 
  34 
Conclusion  35 
 36 
When the limitations are known, LC-MS/MS is useful in identifying cases of occult poisoning; 37 
identifying patients who have ingested multiple substances and/or an unknown substance and 38 
when targeted towards child protection. As LC-MS/MS is an expensive test, it should be used 39 
judiciously in LMICs. 40 
 41 
Key words: Poisoning, Africa, children, mass spectrometry, LC-MS/MS toxicology results in 42 
poisoning cases 43 
 44 
 45 
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Paediatric poisoning is a common presentation to emergency departments worldwide.(1, 80 
2)Though it has a good prognosis, it is an important cause of both morbidity and mortality.(1, 3) 81 
In 2016 it was responsible for 6 268 554 disability adjusted life years (DALYs) globally, with 82 
children less than 15 years accounting for 45% of these DALYs.(4) In a study done in South Africa, 83 
poisoning was responsible for 5.7% of all hospital admissions.(2) While, a retrospective patient 84 
folder review carried out at a hospital in Johannesburg, indicated that toxin ingestion was 85 
responsible for 17% of the admissions in to the paediatric intensive care unit.(5) 86 
 87 
In 2016, poisoning resulted in 31 400 unintentional deaths globally in children less than 15 years 88 
of age.(6) The death rate of poisoning was higher in low-and middle income countries (LMICs), 89 
with LMICs accounting for 69% of the deaths that year.(6) Despite the higher death rates in 90 
LMICs, data on the incidence of paediatric poisoning is more accurate in high-income countries 91 
(HICs) where poison control centers have been established and poisoning registries are kept.(1) 92 
 93 
Risk factors for poisoning include age, sex and environmental factors such as neglect.(3, 7) Child 94 
abuse, in particular neglect,  is a big problem in low resource settings such as in Africa, especially 95 
in the under-5 population.(8-11) This under-5 population is the age group with the highest 96 
incidence of poisoning.(1-3, 7, 12-14) In LMICs, neglect may present as accidental poisoning as 97 
children are often left unsupervised, while child abuse may present as intentional or occult 98 




The role of investigations in poisoning is controversial but may be of benefit in occult poisoning, 101 
where it is difficult to confirm the presence and cause of poisoning.  Point-of-care urine drug 102 
screen (POCUDS) testing is cost effective and readily available, able to give immediate results but 103 
has several disadvantages, such as, a high false positive rate; can only screen for a limited number 104 
of drugs; inability to quantify the drug; inability to name the drug, as it can only identify the drug 105 
class and the risk of false negatives if the drug in question is below the threshold cut-off for 106 
detection.(18-22)  107 
 108 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) on the other hand, is a good 109 
confirmatory test.(18, 20) Unlike POCUDS, it has a higher sensitivity and specificity and has other 110 
advantages, such as, the increased breadth of substances that it can detect and its ability to 111 
identify and quantify drugs and their metabolites by name, and not just by the drug class.(18, 21, 112 
23, 24) The main problem with LC-MS/MS, however, is that it is expensive and may have a long 113 
turnaround time.(18, 19, 21) 114 
 115 
Most of the studies done on the use of LC-MS/MS in poisoning have been done in a retrospective 116 
manner and in high-income settings.(21) Additionally, few of these studies have included 117 
children.  The role of LC-MS/MS in LMICs, where the number of cases of child abuse and neglect 118 
are high and the resources to manage poisoned children are severely constrained, is not clear. Its 119 
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use may be able to assist in identifying high-risk children in households that need social (child 120 
protection) interventions. 121 
 122 
This study aims to describe the prevalence of LC-MS/MS confirmed poisoning in children who 123 
presented to a LMIC paediatric tertiary hospital over a period of a year, with an emphasis on the 124 




The study was done at Red Cross War Memorial Children’s Hospital (RCWMCH), a public 129 
children’s hospital that provides secondary and tertiary health care services to children less than 130 
13 years, living in urban, peri-urban and informal settlements. The hospital manages 131 
approximately 35 000 non-trauma emergency care patient-visits each year. A substantial 132 
proportion of the patients come from extremely poor and marginalized communities.(25) The 133 
children in the catchment area of RCWMCH are not only vulnerable because of poverty but also 134 
because of the increase in substance abuse in formal and informal settlements in the Western 135 
Cape Province of South Africa.(8, 26, 27) 136 
 137 
Study design 138 
The study prospectively enrolled patients with suspected poisoning admitted to the RCWMCH 139 
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from the 1st of January 2017 to the 31st of December 2017, in a cross-sectional design. 140 
 141 
Participants 142 
All patients admitted at RCWMCH with suspected poisoning were eligible for recruitment into the 143 
study if their legal guardians were willing to sign consent for them to be included. Patients who 144 
ingested corrosives requiring surgical intervention were excluded from the study.  145 
 146 
Data collection and procedures 147 
After consent, data on demographic information, clinical presentation and results of 148 
investigations done by the attending clinician were taken, history was taken from the caregiver to 149 
establish possible causes of poisoning. The patient was followed up over the period of admission 150 
and management including clinical outcomes was recorded. The Poisoning Severity Score (PSS) 151 
was used to grade the severity of poisoning at admission (Table 1).(28)  152 
 153 
  154 
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Table 1: PSS grading  
Grade Description 
None No symptoms or signs related to poisoning 
Minor Mild, transient and spontaneously resolving 
symptoms 
Moderate Pronounced or prolonged symptoms 
Severe Severe or life-threatening symptoms 
Fatal Death 
PSS: poisoning severity score.  From Hans E Persson et al, 1998, Poisoning Severity Score. Grading of Acute Poisoning 
 155 
Toxicology investigation 156 
A urine sample from eligible participants was sent to the laboratory for LC-MS/MS to establish the 157 
cause of poisoning. In addition, the attending clinician and laboratory were consulted for any 158 
leftover blood specimen after laboratory tests ordered by the attending clinician were completed 159 
that could likewise be tested on LC-MS/MS. Study participants were not bled solely for the study. 160 
 161 
The LC-MS/MS unit used for this study was the, AB Sciex 3200 QTRAP (© 2013 AB Sciex Pty. Ltd., 162 
AB Sciex, 500 Old Connecticut Path, Framingham MA 01701-4574) unit, housed in the Division of 163 
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Clinical Pharmacology, University of Cape Town, Groote Schuur Hospital, Cape Town. At the time 164 
of the study it had a library of 120 prescription drugs, over the counter medicines, illicit drugs and 165 
some of their metabolites.  The library did not include pesticides or herbal compounds used in 166 
traditional medicines.  167 
 168 
Due to the limited availability of the LC-MS/MS unit, samples were tested in batches. Once 169 
collected, samples were registered and transported to the laboratory where they were stored at 170 
4 °C until analysis. The median turnaround time (TAT) for obtaining a result was 5 (interquartile 171 
range, (IQR) 3 – 7) days for urine LC-MS/MS and 6 (IQR 4 -7) days for blood LC-MS/MS. A total of 172 
five patients had LC-MS/MS results within 24 hours.   173 
 174 
Trained personnel ran the samples and interpreted the results.  For quality control, internal 175 
standards were added to each sample as part of the sample preparation. Each run included 176 
blanks, as well as positive and negative controls to ensure accurate results.(29, 30)  177 
 178 
In order to observe for possible substance degradation, compound stability tests were done on 179 
the LC-MS/MS unit. A commercially obtained control, a system suitability test (SST) (Restek® 180 
Corporation) was run daily. The kit contains 8 compounds of known concentrations. The peak 181 
areas of each compound were observed to confirm that the instrument performance and 182 
sensitivity were optimal and at the same time to observe for possible compound degradation, by 183 
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comparing these areas to previously acquired data.  184 
  185 
As poisoning is defined  by the presence of clinical (somatic and/or mental) manifestations, or 186 
laboratory and/or electrocardiographic abnormalities resulting from exposure to a substance that 187 
can lead to harmful clinical effects(31), once all the toxicology investigations and clinical 188 
presentations were analysed, the authors classified  the cases into one of three groups: 189 
substance-intake-unlikely, substance-intake-likely or substance-intake- unclear. The substance-190 
intake-unlikely group were patients whose clinical presentation could be explained by an 191 
alternative medical diagnosis and were, therefore, not considered poisoning cases even though 192 
they were admitted as cases of suspected poisoning. The substance-intake-unclear group were 193 
patients whose clinical presentation could not be explained by a medical diagnosis and whose 194 
toxicology investigation results were not indicative of poisoning. The substance-intake-likely 195 
group were those patients whose clinical presentation could be explained by a toxic substance 196 
(even in the absence of an LC-MS/MS identified substance) and were therefore considered 197 
poisoning cases, even in the absence of symptoms.  198 
 199 
Irrespective of laboratory results, for the purposes of our study, poisoning cases were also 200 
clinically divided by the authors into three groups: substance known (history of exposure to a 201 
known substance), substance unknown (history of exposure to an unknown substance) and occult 202 
poisoning (no history of poisoning, but clinical presentation in keeping with poisoning). 203 
 204 
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Data analysis  205 
Statistical analyses were done using STATA® 14.0 (StataCorp LLC, College Station, Texas, USA). The 206 
demographic characteristics and clinical findings at presentation were tabulated to provide a 207 
background description of the study population. All substances that tested positive with LC-208 
MS/MS were described. Percentages and their 95% confidence intervals in outcomes of interest 209 
were used to depict proportions of categorical variables while medians with interquartile ranges 210 
were used to summarise continuous variables. The χ2 test or Fisher’s exact test were used to 211 
assess the strength of association between two categorical variables as appropriate. A 212 
significance level at a two-tailed P<0.05 was used for all analyses. 213 
 214 
Results 215 
Demographic Data 216 
A total of 228 cases of suspected poisoning were screened of which 152 were included (Figure 1).  217 
The median age of the included children was 39 (IQR 25-61) months, of whom 86 (56%) were 218 
male and 113 (74%) were below 5-years-of age (Table 2).  219 
  220 
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Figure 1: Study participant flow chart 221 
 222 
Legend: LC-MS/MS- liquid chromatography tandem mass spectrometry 223 
 224 
  225 




191 cases with consent
39 no LC-MS/MS result
152 cases with urine and/or blood LC-MS/MS
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Table 2: Baseline characteristics of the study population (N =152) 
Variable n (%) 
Male 86 (56%) 
Age < 1 year 14 (9%) 
1- 5 years 99 (65%) 
 >5 – 12 years 31 (21%) 
> 12 years 8 (5%) 
Housing Formal 96 (63%) 
Informal 39 (26%) 
Unknown 17 (11%) 





Toxicology results 228 
A total of 146 (96%) urine samples from the 152 study participants were analysed by LC-MS/MS 229 
after six samples were lost due to leakage in transit (figure 2). For 80 (53%) participants, there 230 
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was sufficient left-over blood specimen in the laboratory for LC-MS/MS testing. This included the 231 
six participants whose urine samples had been lost to leakage. 232 
Figure 2: LC-MS/MS samples tested 233 
 234 
Legend: LC-MS/MS - liquid chromatography tandem mass spectrometry 235 
  Altogether, in 89/152 (59%) participants a substance was detected (Figure 3). In 16 (18%) of 236 
these the detected substances were iatrogenic secondary to administration of in-hospital care or 237 
therapy given at home. After discounting the iatrogenic substances or medicines given at home 238 
73 of 152 (48%, 95% CI 40 – 56%) participants had a substance detected by LC-MS/MS.  239 
  240 
26 | P a g e  
 
Figure 3: Substance detection by LC-MS/MS241 
 242 
Legend: LC-MS/MS – liquid chromatography tandem mass spectrometry 243 
 244 
In total, 128 (84%) of the children, 71 (55%) in whom a substance was detected on LC-MS/MS, 245 
were classified as genuine cases of poisoning (substance-intake-likely), while 15 (10%) of the 152 246 
were classified as unlikely to have been poisoned (substance-intake-unlikely) (Figure 4).  In nine 247 
(6%) of the children it was not clear whether poisoning had taken place or not (substance-intake-248 
unclear). 249 
 250 
  251 
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Figure 4: Substance detection by LC-MS/MS according to classification 252 
 253 
Legend: LC-MS/MS – liquid chromatography tandem mass spectrometry 254 
 255 
Despite being classified as genuine cases of poisoning, 57 (45%) of the 128 substance-intake-likely 256 
children did not have a causative substance identified via LC-MS/MS and 49 (38%) children had no 257 
substance identified and eight (6%) had iatrogenic substances identified (Figure 4). The median 258 
TAT for the 57, who were substance-intake-likely cases but in whom the LC-MS/MS was negative, 259 
was 5 (IQR 3- 9) days for urine LC-MS/MS and 5 (IQR 4 – 9) days for blood. TAT of the 71 poisoning 260 
cases that had positive LC-MS/MS was 5 (IQR 2 – 7) days for urine and 6 (IQR 4-7) days for blood. 261 
 262 
In 26 (20%) of the substance-intake-likely group in whom no substance was detected, the 263 
suspected substance was not in the LC-MS/MS reference library used. Of these, 17/26 (65%) were 264 
pesticides (11 rat ‘poison’, 4 ‘cockroach poison’, 1 ‘tick poison’ and 1 undefined pesticide). 265 
 266 
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There were eight organophosphate poisonings cases in the substance-intake-likely group. In two 267 
of the eight organophosphate poisonings, LC-MS/MS detected other substances (bromazepam 268 
and diphenhydramine), ingested by the same patients. Likewise, in one of the four cases of iron 269 
poisonings, trimethoprim was concomitantly identified by LC-MS/MS. Eight patients who had 270 
ingested hydrocarbons, three ethanol ingestions, two turpentine, and one each of petrol, 271 
eucalyptus oil and paraffin ingestion, had no additional substances detected by LC-MS/MS.  272 
 273 
Five (4%) patients in the substance-intake-likely group presented with a history of ingesting an 274 
unknown substance, and the identity of the unknown substance was not identified via LC-MS/MS.  275 
Cannabis was detected via LC-MS/MS in a tablet brought by one of these patients but could not 276 
be confirmed in the patient’s samples.  277 
 278 
Nine patients in the substance-intake-likely group presented after ingesting a substance found in 279 
the LC-MS/MS library and yet the substance was not detected by LC-MS/MS, despite seven 280 
patients being symptomatic from the suspected substance. Four of the nine patients had both 281 
blood and urine LC-MS/MS done, while five had only urine LC-MS/MS done .The drugs that were 282 
not detected were the following, clonazepam, diazepam, lorazepam, phenytoin, alprazolam, 283 
cannabis, antiretrovirals (tenofovir/emtricitabine/efavirenz), chlorpromazine and tricyclic 284 
antidepressant. Six of the patients had vomiting induced by the care giver in an attempt to 285 
decontaminate. Furthermore, two of these patients received charcoal before the LC-MS/MS was 286 
done (one case of tricyclic antidepressant toxicity and one case of chlorpromazine ingestion). The 287 
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median TAT for these nine patients was seven days with a range of 1 – 13 days. 288 
 289 
Of the 15 patients, in the substance-intake-unlikely group, LC-MS/MS detected no substances in 290 
eight (53%) and identified iatrogenic medicines in seven (47%) Figure 4). Of the nine substance-291 
intake-unclear patients, one patient had a positive result due to iatrogenic medicines and two had 292 
positive results, but the drugs identified could not explain the clinical presentation. 293 
 294 
Presenting history versus LC-MS/MS results in poisoning cases (substance-intake-295 
likely) 296 
When the 128 children in the substance-intake-likely group was further analysed according to the 297 
history obtained from the caregiver, 24 (19%) participants had no history of exposure to a 298 
substance (occult poisoning). (Figure 5) In those who had occult poisoning, the suspicion of 299 
poisoning came from the clinician’s examination findings, and/or investigations done by the 300 
attending clinician. The substance detection rate of LC-MS/MS, after removing iatrogenic 301 
medicines, was then analysed in three different groups, known substance, unknown substance 302 
and occult poisoning. (Figure 5) 303 
  304 
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Figure 5: Number and proportion of substance detection rates on LC-MS/MS in substance-intake-305 
likely group  306 
 307 
Legend: LC-MS/MS liquid chromatography tandem mass spectrometry 308 
 309 
In children with occult poisoning, LC-MS/MS was able to identify the substance in 22/24 (92%) 310 
compared to 42/88 (48%) when a guardian reported ingestion of a known substance (p=<0.0001), 311 
and 7/16 (44%) when a guardian reported ingestion of an unknown substance (p value = 0.003) 312 
(Figure 5). 313 
 314 
In the 22 (92%) cases of occult poisoning, in which LC-MS/MS identified a substance, the 315 
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patients, in whom LC-MS/MS identified a substance not in keeping with the clinical presentation, 317 
concomitant organophosphate poisoning was identified by alternative means. In these two 318 
organophosphate cases LC-MS/MS identified a substance that would have otherwise been 319 
missed. All 15 patients who had presented with an unknown substance and 23 (96%) of the 24 320 
cases of occult poisoning had neurological symptoms. 321 
 322 
In the patients who reported ingesting a seemingly ‘known’ substance, the substance found on 323 
LC-MS/MS was different in 15/88 (17%) patients. In these 15 cases, six were asymptomatic, while 324 
four had symptoms consistent with the substance found on LC-MS/MS. 325 
 326 
Overall, 18/128 (14%) cases of poisoning would have been missed had LC-MS/MS not been used 327 
in this study. 328 
 329 
Causes of poisoning 330 
In 106/128 (83%) of the cases, poisoning was unintentional. There were however 6/128 (5%) cases 331 
of attempted homicide and 5/128 (4%) of attempted suicide (Table 3). 332 
  333 
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Table 3: Causes of poisoning (Intent), n=128 334 
Intention Frequency (N=128) 
 
Unintentional 
Self 99 (77.3%) 
Caregiver medication error 1 (0.8%) 
Traditional medicine  3 (2.3%) 
Iatrogenic 3 (2.3%) 
 
Intentional 
Attempted homicide 6 (4.7%) 
Caregiver/adult but not attempted 
homicide 
6 (4.7%) 
Attempted suicide 5 (3.9%) 
Self but not suicide attempt  1 (0.8%) 
Undetermined 4 (3.1%) 
 335 
Of the six attempted homicides, two cases involved siblings from a family that had three deaths 336 
due to the same organophosphate poisoning event. In one of the patients who had been given 337 
traditional medicines, norfluoxetine, trimethoprim and diphenhydramine were detected by LC-338 
MS/MS. Four of six children given substances intentionally by adults received drugs of abuse- two 339 
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received cannabis, one received methamphetamine and the other ethanol. The other two 340 
patients, presented with neurological symptoms, and the substances administered could not be 341 
identified.  342 
 343 
Drugs identified by LC-MS/MS 344 
LC-MS/MS was able to identify a total 45 different drugs after removal of iatrogenic medicines 345 
and medicines given at home (Figure 6). In the 128 substance-intake-likely cases, LC-MS/MS 346 
identified 140 substances. The most common causative group identified by LC-MS/MS was 347 
antihistamines found in 24 (19%) patients, followed by opiates in 23 (18%) and antipsychotics in 348 
17 (13%). The most common drugs were chlorpheniramine and haloperidol found in 9 (7%) 349 
patients each. LC-MS/MS was able to identify multiple drugs in 40 (31%) of the substance-intake 350 
likely group. 351 
 352 
  353 
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Figure 6: Drug classes identified by LC-MS/MS 354 
 355 
 356 
Legend: LC-MS/MS: liquid chromatography tandem mass spectrometry 357 
 358 
Comparison of urine and blood LC-MS/MS results 359 
Seventy-four (74) patients had both urine and blood samples analysed on LC-MS/MS. Urine and 360 
blood LC-MS/MS yielded the exact same result in 48 (65%) patients (Table 4).  In 18 (24%) of the 361 
participants with paired samples, more substances were detected in urine but not in blood, while 362 
in 4 (5%) samples, more substances were detected in blood but not urine.  363 
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Table 4: Comparing urine and blood LC-MS/MS positivity rate (N = 74) 365 
LC-MS/MS Result Frequency (%) 
No detected substance in urine and blood 27 (36%) 
Same substance detected in urine and blood 21 (28%) 
Different substance detected in urine and blood 4 (5%) 
Substance detected in urine and blood, but more substances found in urine 7 (9%) 
Substance detected in urine and blood, but more substances found in blood 3 (4%) 
Substance detected in urine but not in blood 11 (15 %) 
Substance detected in blood but not in urine 1(1%) 
Total 74 (100%) 
LC-MS/MS: Liquid chromatography tandem mass spectrometry  
 366 
Clinical systems involved in the poisoning cases 367 
Of the 71 positive LC-MS/MS results in the substance-intake-likely group, the substances 368 
identified by LC-MS/MS were in keeping with the clinical presentation in 55/71 (77%) participants. 369 
Nine (13%) of the 71 positive LC-MS/MS cases in the substance- likely-group were asymptomatic 370 
even though a substance was detected by LC-MS/MS.  371 
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 372 
The most common system involved was neurological, found in 88 (69%) of the substance-intake-373 
likely cases followed by gastrointestinal found in 49 (38%), cardiovascular in 26 (20%) and 22 374 
(17%) were asymptomatic. Of the 49 that had gastrointestinal symptoms 24 (49%) had the 375 
presence of the confounder of intentional induction of vomiting by the caregivers using manual 376 
induction, milk and/or saltwater. LC-MS/MS detected a substance in 58 (66%) out of 88 poisoning 377 
cases with neurological symptoms compared to 13 (33%) of the 40 without neurological 378 
symptoms (p<0.0001).  379 
 380 
Substance-intake-likely management and outcome 381 
According to the PSS, most cases were classified as moderate, 51 (40%), while 12 (9%) were 382 
classified as none and 42 (33%) were minor and therefore required minimal supportive care. Of 383 
the 23 (18%) children with a PSS severe grade, 10 (8%) required admission to the Paediatric 384 
Intensive Care Unit (PICU). Twenty-nine children (23%) were given an antidote and 6 (5%) 385 
received activated charcoal. There were no deaths. 386 
 387 
Individualized social intervention was instituted in all the patients with removal and emergency 388 
placement occurring in six patients. All six attempted homicide cases were referred for forensic 389 
investigation. The mother was the perpetrator in four of the attempted homicide cases. LC-390 
MS/MS detected a substance in three of the attempted homicides. A total of 22 (14%) patients 391 
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Our study describes the prevalence of LC-MS/MS-confirmed paediatric poisoning in a LMIC 396 
setting. LC-MS/MS was particularly helpful in occult poisoning where it was able to identify over 397 
90% of the substances, as well as in identifying multiple substance ingestion. In addition, our 398 
study indicates the urine sample as having a higher detection rate for identifying potential 399 
ingested substances when compared to a blood specimen. According to the authors’ knowledge, 400 
this study is the first prospective one of its kind done in a LMIC setting.  401 
 402 
Similar to previous studies, most of the poisoning cases were males between the ages of one and 403 
five years.(1-3, 7, 12-14) This is likely due to the developmental stage toddlers are in, that 404 
involves curiosity about the world and a desire to explore it.(13, 14) 405 
 406 
Previous literature has demonstrated shortfalls with urine point of care drug screen 407 
immunoassay, therefore, a positive point of care urine drug screen result  requires a confirmatory 408 
test, such as mass spectrometry.(18, 20-22) After excluding iatrogenic medicines and therapy 409 
given prehospital, LC-MS/MS was able to detect substances in 48% of all study participants and 410 
55% in the substance-intake-likely cases.  411 
 412 
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Twenty-six patients in this study reported ingesting a substance that was not in the library. This 413 
was the main reason for a negative LC-MS/MS result in poisoning cases, in this study. This 414 
indicates that the ability of LC-MS/MS to detect a substance is limited by the extent of the LC-415 
MS/MS library available at the time. Notably, the LC-MS/MS library can be updated and additional 416 
drugs/substances added.(18, 19, 21) The LC-MS/MS used in this study could detect the presence 417 
of various drugs in concentrations as  low as 20ng/ml. Despite this high sensitivity, nine poisoning 418 
cases who had ingested drugs in the LC-MS/MS library were not detected. The possible 419 
explanations are varied and include, that the concentration of these drugs in the analysed 420 
samples may have been below the limit of detection of the instrument, either due to rapid 421 
metabolism or elimination. Six of the nine patients had vomiting induced by the care givers which 422 
could have led to decontamination, before the patient could absorb the drug. Notably, two of 423 
these patients were given activated charcoal. Worryingly, the first was a tricyclic antidepressant 424 
overdose, that LC-MS/MS did not detect. The second was a symptomatic chlorpromazine 425 
ingestion. This ingestion was witnessed, and the patient was given activated charcoal before the 426 
LC-MS/MS was done. It is possible that LC-MS/MS may have been limited by failure to detect 427 
substances that are eliminated via the hepatobiliary system which may not have been detectable 428 
in urine, as well as substances with a short half-life that may have degraded before sampling or 429 
analysis. These reasons are limitations of LC-MS/MS that the clinician needs to be aware of when 430 
utilising LC-MS/MS. All nine drugs that the LC-MS/MS failed to identify, and yet were in the LC-431 
MS/MS library, are excreted in urine except for tenofovir, which is mainly excreted in faeces. A 432 
study done on sample stability indicated that substance degradation was dependent upon the 433 
type of substance and the temperature at which a sample is stored.(32) Substances stored at  434 
25°C, 4 °C and -20°C were later extracted and analysed at 15, 60 and 90 days and the average 435 
39 | P a g e  
 
relative peaks on these days were compared with the average relative peaks at baseline.(32) The 436 
study concluded that the best temperature to store samples is -20°C, although even at 4°C the 437 
substances could still be detected even if the peaks were lower.(32)  The samples in our study 438 
were stored  at 4°C, and therefore substance degradation cannot be ruled out. 439 
 440 
There are other substances that the LC-MS/MS could not detect, and these included: volatile 441 
substances such as hydrocarbons, which require a different method i.e., gas mass spectrometry 442 
for detection; organophosphates because they metabolize fast and metals such as iron. As a 443 
result, though a positive LC-MS/MS result is beneficial, a negative LC-MS/MS result does not rule 444 
out poisoning.  445 
 446 
Due to circumstantial evidence, such as an open bottle or missing tablets, the causative agent in 447 
paediatric poisoning is generally obtained from history, which means laboratory investigations to 448 
identify the cause of poisoning is often regarded as not necessary. However, in our study, LC-449 
MS/MS found that of the 88 poisoning cases that had ingested a seemingly ‘known’ substance, 450 
almost a fifth (17%), of the patients had ingested a different drug from that reported by the 451 
caregiver. This has management implications as the wrong drug level can be requested from the 452 
laboratory and the wrong antidote given while the right one is delayed.  453 
 454 
Most of the studies and reports that look at the causes of poisoning in children do not highlight 455 
multiple drug exposure as an important cause of poisoning. (1, 7, 13, 33) Veale et al., in a study 456 
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that included both adults and children, indicated that only 13.8% of the poisoning cases had been 457 
exposed to multiple drugs.(12) While a retrospective study done at the same children’s hospital 458 
as our study setting, indicated that less than 10% of the children who presented with poisoning 459 
had been exposed to more than one toxin. (3) Contrary to the previous mentioned studies, that 460 
reported low rates of multiple drug ingestion in children, in our study, LC-MS/MS detected 40 461 
(31%) cases of  multiple drug ingestions further demonstrating the ability of LC-MS/MS in 462 
positively identifying multiple drug ingestions. The use of laboratory specific drug levels to detect 463 
multiple drugs requires the clinician to request different specific drug levels to be run, in contrast, 464 
LC-MS/MS requires only one sample to be run to identify multiple drugs and/or substances. 465 
Without LC-MS/MS multiple drug ingestions would have been missed in this cohort of children. 466 
However, it is important to note that LC-MS/MS was not able to differentiate between multiple 467 
drugs from a single medicine with two or more drugs, and that which involved ingestion of 468 
multiple separate drug formulations. 469 
 470 
The most common drug classes found in our study were antihistamines (19%), opiates (18%), 471 
antipsychotics (13%) antidepressants (12%) and antiepileptics (10%), while the most common 472 
drugs detected on LC-MS/MS were chlorpheniramine and haloperidol. This may explain the high 473 
frequency (69%) of neurological symptoms in the cases with likely substance ingestion. 474 
Historically, agro-based and non-drug chemicals were the main causes of poisoning in LMICs.(1, 3, 475 
7, 33-35) There is a need to strengthen preventative campaigns in LMICs as pharmaceuticals are 476 
becoming important causes of poisoning.(12, 34) 477 
 478 
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Traditional medicine use is not uncommon in LMICs, there have been previous reports of these 479 
medicines being adulterated, as was the case in one of our patients who ingested   traditional 480 
medicine and LC-MS/MS identified norfluoxetine, trimethoprim and diphenhydramine.(24, 36-39)  481 
While, both blood and urine samples can be analysed by LCMSMS, urine is usually readily 482 
available as a non-invasive specimen with minimal discomfort to children. Furthermore, unlike in 483 
blood, drugs  and their metabolites are known to remain in urine for longer (up to one week) post 484 
last exposure depending on the drug.(20, 21, 40) This gives a greater window of opportunity to 485 
still identify a substance after ingestion, especially when this is unknown or occult. 486 
 487 
It is important to note that the clinical outcome was not altered using LC-MS/MS, this 488 
corresponds to previous studies, and in our study was because of the long turnaround time, with 489 
a median of 5 ( IQR 3 – 7) days  for urine LC-MS/MS and 6 (IQR 4 -7) days for blood.(19, 21) In our 490 
study, the turnaround time was prolonged because the test samples were batched. The other 491 
major limitation of mass spectrometry is its expense.(18, 19) However, as technology has 492 
improved, mass spectrometers have become cheaper and faster.(18, 23, 29, 41-43) A study by 493 
Caspar et al., demonstrated its value in 24/7 toxicology by analysing 22 drugs and active 494 
metabolites in a qualitative and quantitative manner.(30) In the study done by Caspar et al., the 495 
total run time for a test was 11 minutes, extrapolated to the emergency care setting, such run 496 
times would enable the clinician to treat the patient accordingly and in a timely point-of-care 497 
manner.(30, 43) It would also avoid unnecessary treatment procedures in those that do not 498 
require them. The LC-MS/MS system may also be made more efficient using automation, this 499 
reduces the need for skilled personnel to run the equipment.(18, 21) 500 
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 501 
LC-MS/MS identified 92% of all cases of occult poisoning and the substance identified by LC-502 
MS/MS were in keeping with the clinical presentation in 91% of the cases of occult poisoning.  503 
There is limited data on the prevalence of occult poisoning in children especially in LMICs, in our 504 
study, one in five (19%) of the poisoning cases were due to occult poisoning. Occult poisoning was 505 
more likely if the patient had acute unexplained neurological symptoms that were not due to an 506 
infection or trauma. This makes LC-MS/MS of value in the area of child protection, when children 507 
may be poisoned intentionally.  Child protection is also required in all cases of unintentional 508 
poisoning that are due to neglect. In this study six children required removal from the adverse 509 
environment as well as further child protective measures.  510 
 511 
Limitations 512 
Our study is limited by a small sample size which reduced our ability to stratify the data further by 513 
causes of poisoning. Furthermore, we were not able to include unnatural home deaths that 514 
presented to the mortuary. As alluded to earlier, the LC-MS/MS library used did not contain an 515 
exhaustive list of possible substances.  516 
 517 
Conclusion 518 
In conclusion, the use of LC-MS/MS in toxicology screening is novel in the African paediatric 519 
population. It appears to be of greatest value in the paediatric patient who presents with occult 520 
poisoning or has ingested multiple and/or unknown substances. It was less helpful in those that 521 
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had ingested a known single substance unless the substance found on LC-MS/MS was found to be 522 
different. Though a robust test, clinicians need to be aware of its shortfalls. In high-risk settings, it 523 
can be utilized in community toxicovigilance and child protection. Finally, the authors could not 524 
find guidelines on the use of investigations, in particular LC-MS/MS, in LMICs, and because LC-525 
MS/MS is an expensive test, we recommend that a protocol for its judicial use in LMICs be 526 
developed.   527 
 528 
“Key messages” box 529 
Section 1: What is already known on this subject 530 
The use of investigations in paediatric poisoning is controversial. There is a paucity of prospective 531 
data on the use of LC-MS/MS in paediatric poisoning in LMICS, where resources are constrained 532 
and risk factors for poisoning such as neglect and child abuse are high. 533 
Section 2: What this study adds. 534 
LC-MS/MS is beneficial in the paediatric patient who presents with occult poisoning or has 535 
ingested multiple and/or unknown substances. Requesting clinicians need to be aware of its 536 
shortfalls. In high risk settings, it can be utilized in community toxicovigilance and child 537 
protection. Due to its expense, a protocol needs to be developed for its judicial use in LMICS. 538 
 539 
  540 
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Appendix A: Study protocol 
Protocol V11 
A prospective cross-sectional study to assess the value of mass spectrometry in the 
management of paediatric poisoning at Red Cross War Memorial Children’s Hospital 
 
MMED Student: Dr Norbertta Washaya1, 2 
 
Principal Investigator 
Dr Heloise Buys1, 2  
 
Co-Investigators 
Dr Rudzani Muloiwa2, 4  
Professor Peter Smith3, 4  
Alicia Evans3 
1 Red Cross War Memorial Children’s Hospital 
2 Department of Paediatrics and Child Health, University of Cape Town 
3 Division of Clinical Pharmacology, University of Cape Town 
4 Groote Schuur Hospital 
Background 
Statement of the problem 
According to a World Health Organization report, poisoning is the 4th biggest cause of 
unintentional injury after road traffic injuries, fires and drowning1. It accounts for about 7% of all 
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accidents in children under 5 years and is implicated in about 2% of all childhood deaths in the 
developed world, and over 5% in developing countries2. As a cause of emergency unit visits, its 
incidence varies with each location with one study documenting an incidence of 0.28% and 
another that of 3%3, 4.  
Childhood poisoning is rarely fatal in developed nations, where good data collection and various 
public health preventative methods have been implemented 1, 5. However, mortality is high in 
Africa and low  
and middle income countries with the highest fatality rates noted in those less than 1 year of 
age1. Despite the higher fatality rates in developing nations, data on childhood poisoning remains 
poor in developing nations5.  
This burden of childhood poisoning goes beyond mortality as it puts a significant burden on the 
health system in terms of morbidity and costs incurred with case management7. In order to curb 
this negative effect on the health system, work is required to both identify and implement 
preventative strategies to decrease the number of cases of paediatric poisoning7. 
In South Africa a number of the cases of paediatric poisoning are managed at tertiary hospitals, 
Red Cross War Memorial Children’s Hospital (RCWMCH) is an example of a tertiary hospital that 
manages paediatric poisoning. RCWMH is a public children’s hospital that provides secondary and 
tertiary health care services to children living in peri-urban settlements. The hospital manages 
approximately 260 000 patient visits each year8. A significant percentage of the patients come 
from exceptionally poor and marginalized communities8, namely informal settlements. It has 
been noted that 8% of all children under the age of 18 years in the Western Cape live in informal 
settlements, with children under the age of 5 contributing the largest percentage of 42%9. This 
under five age group is at the greatest risk of unintentional poisoning because of their innate 
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exploratory behavior10.  
The causative agents of poisoning in children varies with each location, where the causes in 
developed nations differ from the causative agents in developing nations10. A study done at 
RCWMCH illustrated a difference in the causative agents in patient’s residing in different 
suburbs6. However, despite the differences in communities, the number one cause of paediatric 
poisoning was kerosene (paraffin) while drugs were the most common toxic group6. 
Despite the magnitude of the burden of paediatric poisoning the global trend shows a steady 
decline in the incidence of paediatric poisoning4, 6. Recent data from the Information 
Management Unit at RCWMCH illustrates a similar trend as there was a steady decline in the 
number of patients presenting with suspected poisoning to the medical emergency department 
from 224 cases in 2010 to 124 cases in 2014. This decline may be attributed to increased 
community awareness as well as initiatives and campaigns such as child safety. It also coincides 
with the opening of two district hospitals, Khayelitsha District Hospital and Mitchells Plain District 
Hospital. Despite the decline, data from the same source shows that the offending substance was 
not confirmed in 89, 5% of the cases. This not only has medical implications but potential 
deleterious social implications for the child who will return to the same home environment that 
predisposed them to unintentional poisoning. 
 
Investigation of paediatric poisoning 
The role of investigations in paediatric poisoning remains unclear as there is currently no agreed 
upon gold standard11, 12. This has led to various guidelines been drawn up to assist emergency 
departments on the laboratory tests to use in different poisoning scenarios11.In a number of 
centers the need for a toxicology screen depends upon the clinical scenario and is rarely needed 
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in those who have an unintentional known substance ingestion and are asymptomatic or have 
clinical features consistent with the history12. However, a toxicology screen becomes valuable 
when12 
• The clinical picture of the patient remains unexplained 
• Antidote administration depends upon rapid identification of the toxic agent 
• And when there is a suspicion of child abuse or Munchausen syndrome by proxy 
 
Urine immunoassay has been identified as a cost effective toxicology screen. However, like all 
screening tests it has its limitations. The limitations of the urine immunoassay drug screens 
include the following: 13 
• Limited number of street drugs 
• Inability to quantify drug 
• False positives due to chemically similar compounds 
• False negatives for example when drug level is below the threshold level 
• Affected by the pharmacokinetics 
• Positive result requires confirmatory test with mass spectrometry 
 
Other modalities that have been proposed to aide investigation of poisoning include the use of 
Mass Spectrometry. Mass spectrometry has the advantage of detecting more poisons or toxins 
when compared to its immunoassay counterpart. In a review on paediatric poisoning, the gas 
chromatography/mass spectrometry was able to get positive results in 85% of the samples, while 
the immunoassay test was able to get positive results in only 16% of the samples14.Despite the 
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significant difference, a number of studies, however, show conflicting evidence concerning the 
usefulness of mass spectrometry in toxicology. It has been argued that the use of mass 
spectrometry does not change the management, as management is based mainly on the clinical 
picture15, 16. One study  done in 1999 noted that aside adding significant charges to the patient, 
the comprehensive drug screen, using High Performance Liquid Chromatography (HPLC), had no 
additional clinical benefit when compared to the limited component test15. Fabbri et al., on the 
other hand, concluded that a rapid comprehensive drug screen, such as mass spectrometry, is 
useful in the diagnosis of patients with suspected drug poisoning16. It identifies unsuspected 
drugs in symptomatic patients and excludes drugs in asymptomatic patients16.This is of particular 
importance as patients with negative tests can be safely discharged within a few hours, thus 
avoiding unnecessary admissions and decontamination procedures16. In those with positive 
results their management can then be tailored to the toxin found as well as the clinical severity of 
the patient. Furthermore, there are compounds that can be detected by mass spectrometry that 
are not in any immunoassay kits, such as clozapine and citalopram, which change patient 
management considerably, as they would otherwise be reported as negative.  
 
At RCWMCH the toxicology screen done on each patient rests on the clinician’s clinical suspicion 
in requesting the appropriate test. However, in cases where the history is not clear, as is with a 
number of our cases, appropriate testing to identify the offending agent cannot be carried out. 
Point-of-care toxicology urine screening (Sure slip®) is available in the medical emergency 
department and tests for the following substances: 
1. Methamphemine 
2. Amphetamine 






The National Health Laboratory Services (NHLS) is able to offer testing for the following 
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Because of the limited number of toxins or drugs that we are able to test for in the Medical 
Emergency Department at RCWMH, methods to increase the diagnostic ability, such a mass 
spectrometry, need to be evaluated. This method of mass spectrometry is available at the 
University of Cape Town’s Division of Clinical Pharmacology based at Groote Schuur Hospital and 
offers considerable advantage in that it is able to identify, through targeted analysis, multiple 
substances, as well as prolonged exposure to a substance through the use of hair samples. 
This study is aimed at evaluating the value of mass spectrometry in the management of paediatric 
poisoning at busy health care centers such as RCWMCH; as well as documenting and recording 
the toxins that children ingest, this will further direct appropriate preventative programs. 
Research Question and Objectives of the Study 
Study question  
What is the value of mass spectrometry in the management of paediatric poisoning? 
Research Hypothesis 
Diagnostic mass spectrometry is of no value in the management of paediatric poisoning. 
Aim 
To assess the value of mass spectrometry in the management of paediatric poisoning 
Research Objectives  
1. To describe the demographic characteristics of children who present with paediatric 
poisoning to the RCWMCH 
2. To describe the substances causing paediatric poisoning in patients presenting to the 
RCWMCH  
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3. To determine the proportion of positive tests that are identified by mass spectrometry in 
comparison to the proportion of positive tests that are identified by routine toxicology 
(urine immunoassay and NHLS laboratory tests) 
4. To determine the clinical outcome of children with poisoning managed with the help of 
diagnostic mass spectrometry 
Methodology 
Characteristics of the study population 
All children that present to the RCWMCH with suspected poisoning will be eligible. The list of 




All children that present to Red Cross War Memorial Children’s Hospital with any of the 
following: 
1. Confirmed or suspected acute poisoning from history 
2. Unexplained neurological symptoms such as unexplained altered level of consciousness; 
unexplained seizures 
3. Atypical presentation of diarrhoea and vomiting  
4. Unexplained metabolic derangements for example unexplained acute kidney injury and 
unexplained acute liver failure 
Exclusion criteria: 
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1. Acute food poisoning and  
2. Care- giver refusal to participate 
3. Presentation of poisoning that would not routinely require laboratory investigation e.g 
paraffin poisoning 
 
Recruitment and enrolment 
Will be done through the Medical Emergency Department and the Short Stay Ward 
Study design 
Prospective cross-sectional study will be carried out for a period of 12 months. 
  
When a patient presents with suspected poisoning clinical management and investigations will be 
carried out as per standard protocol. On the specimens collected for routine toxicology screening, 
urine and blood, some urine and blood from the same specimens will be sent for mass 
spectrometry. In relevant cases hair samples will also be collected. 
Once results are available a comparison will be made between samples sent for routine 
toxicology screening and sample sent for mass spectrometry. Each mass spectrometry sample will 
be matched with a routine toxicology screen sample from the same patient specimen. 
 
Research procedures and data collection methods 
Each patient will be managed according to current best clinical practice with AfriTox® being used, 
64 | P a g e  
 
as is routine care, when the ingested substance is known or strongly suspected. 
Investigations:  
1. Urine samples will be collected simultaneously for routine toxicology as well as mass 
spectrometry and be sent off, where possible,  at the same time 
2. When required for appropriate management, blood samples will be collected as well for 
both routine toxicology and mass spectrometry 
3. If parental consent is obtained, a small hair sample will be taken 
A generic data collection sheet will be used to collect demographic data, clinical symptoms, initial 
diagnosis, final diagnosis, management, clinical course and outcome. 
Comparison will then be made between the samples sent for routine toxicology screening and the 
samples sent for mass spectrometry.  
 
ABSciex 3200 QTRAP 
The mass spectrometer that will be used in the study is the ABSciex 3200 QTRAP unit used by the 
UCT Clinical Pharmacology division at Groote Schuur Hospital. It is described as a preliminary 
screening research tool and not a validated diagnostic system. Its library database includes 250 
medicinal drugs or drugs of abuse and some of their metabolites. Sensitivity varies according to 
the compound but the specificity is high. Due to the current logistical framework, during the 
study the instrument will be run once every week. 
 
Shortfalls of Mass Spectrometry 
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1. As indicated earlier it is a screening test and not a validated diagnostic system 
2. Matrix effect, which is defined as the combined effect of all compounds of the sample 
other than the analyte. This interferes with the ionisation process in the Mass 
Spectrometer causing ionisation suppression or enhancement that negatively affects the 
measurement of quantity17. 
3. The cost of running the instrument is expensive and approximates R500 per sample 
 
Data safety and monitoring plan 
Each patient will be given a unique code for identification. The data will then be entered using a 
pass word protected and encrypted Excel spread sheet. 
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Data Analysis and Statistical methods 
Sample size 
 
Based on available data, we estimate that mass spectrometry would be able to confirm diagnosis 
in 50% to 85% of cases of poisoning while routine toxicology will only be able to confirm between 
10% and 30% of the cases. 14,18. Using a type 1 error rate of alpha = 0.05, paired sample sizes of 
103 for each diagnostic method will be required to detect a statistically significant difference with 
80% power using the upper limit (30%) and lower limit (50%) of detection for routine diagnostic 
and spectrometry respectively. Other sample sizes required to detect statistically significant 
difference in proportions of confirmed poisoning are shown in table 1. Data from RCWMCH 
Information Management Unit indicates that we can expect to collect between 150 and 200 
paired samples over a one year period. 
 
Table 1: Sample size for different proportions of confirmed drug poisoning 
























40 50 60 70 80 90 
5 27 19 14 11 8 7 
10 38 25 17 13 10 8 
15 57 33 22 15 11 9 
20 91 45 28 19 13 10 
25 165 66 36 23 16 11 
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30 376 103 49 29 19 13 
 
 
Data management and Analysis 
 
Data will be entered into a password-protected computer on an encrypted Excel database after 
which it will be imported into Stata (StataCorp LP, College Station, TX) for cleaning up and 
analysis. 
 
The demographic characteristics and clinical findings at presentation will be tabulated to provide 
a background description of the study population. All toxins that test positive for routine 
toxicology and/or mass spectrometry will be described. The proportion of patients testing 
positive for different toxins will be calculated for each diagnostic method. Percentages and their 
95% confidence intervals in outcomes of interest will be used to depict proportions of categorical 
variables while medians with interquartile ranges will be used to summarise all continuous 
variables.  Proportions of confirmed diagnosis will be compared between the two diagnostic 
methods as described below. 
 
The χ2 test or Fisher’s exact test will be used to assess the strength of association between two 
categorical variables as appropriate. Continuous variables will be tested for normality and the 
appropriate statistical test used to test for association. To adjust for potential confounders, a 
multivariable model will be used to estimate effect measures using logistic regression or general 
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linear modelling as appropriate. A significance level at a two-tailed P<0.05 will be used for all 
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Dissemination of Information  
 
The data will be prepared for presentation at several venues including a local presentation to the 
Department of Paediatrics and Child Health. A manuscript will be prepared and submitted for 
publication in a peer-reviewed journal.  
 
Description of risks and benefits 
Risks 
Physical 
• Urine collection – urine bags will be used for young children and infants and mid steam 
samples for older children. No suprapubic aspirates or in and out catheter specimens will 
be collected unless it is part of the routine management of the patient 
• Blood Sampling  - risk will be minimised in that the blood will be taken from the same 
sample used for routine toxicology and/or other relevant tests needed for their medical 
management 
• Hair sampling- a very small sample of head hair will be taken by snipping with a pair of 
scissors and only taken if the care giver consents,  or in the case of children aged 7-years 
or older, assents (See appendix 2,3 & 4). 
Psychological 
• Psychological effects of blood sampling  and loss of a small snippet of hair in children 
Social 
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• Identifying substances and or drugs of abuse would lead to a social investigation of the 
home environment 
Benefits 
• Identification of actual ingested substance and thus streamlining management 
• Identification of multiple ingested substances  
• Contact details of parents/guardians will be obtained such that feedback of positive 
results that come after discharge can be given to the family and appropriate social and/or 
clinical intervention will be instituted 
• In the event of identification of a substance of abuse the clinician in charge will be notified 
who will refer the case to the Social Work Department as per our standard protocol. 
Currently the Department of Social Services is involved in all cases of ingestion via the 
hospital Social Work Department. The parents and family will be interviewed and social 
interventions and protective measures as deemed appropriate will be followed depending 
on the findings of the Social Work Department 
• Ability to identify the causes of poisoning would lead to targeted preventative strategies  
• There is limited data on the use of Mass Spectrometry in paediatric poisoning in the 
African context making this study beneficial in providing data in the African context 
• The study will assist in drawing up recommendations on the use of investigations in 
resource limited settings 
 
Informed Consent process 
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Legal guardians of children who present will be requested to give written consent in their 
language of choice for specimens to be sent for mass spectrometry. 
In the event of a patient older than 7 years written assent shall be obtained except in cases where 
the mental status of the patient is impaired. 
 
Limitations of study 
1. The Mass Spectrometer will be run once a week resulting in a delay in access to valuable 
results, but as mentioned the guardian details will be obtained. 
2. Inability of the Mass Spectrometer to identify volatile compounds 
3. Traditional medicine ingestion is common in our setting however the Mass Spectrometer 
in use is unable to identify traditional medicines as we are not able to get reference 
standards to confirm findings 
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Table 2: Budget 
Item Cost per 
patient (Rands) 
Cost per 100 
patients (Rands) 
Cost per 200 
patients 
(Rands) 
Data collection sheets 0,8 80 160 
Stationary (miscellaneous) 5 500 1000 
Patient Mass Spectrometry labels 4 400 800 
Urine Mass Spectrometry 500 50 000 100 000 
Blood Mass Spectrometry 500 50 000 100 000 
Total cost 1009,80 100 980 201 960 
 
There are no sponsors for the study. The cost of Mass Spectrometry and sample storage will be 
borne by the UCT Division of Pharmacology at Groote Schuur. The cost for stationary, patient 
labels and data collection sheets will be borne by the principal investigator. Routine toxicology 
will be done as routine clinical care and so the cost will be covered as per routine practice. 
Study Time lines 
The study is expected to take place over an 18 months period according to the milestones shown 
in table 3. 
Table 3: Study Time line 
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Activity Time frame 
DRC submission 24 June  2016 
Ethics submission 3 October 2016 
Collection of data 1 November 2016 – 30 September 2017 ( 
1year) 
Cleaning Data 1 November  2017 – 30 November 2017 (1 
month) 
Data Analysis 1 December 2017 – 31 December 2017 (1 
month) 
Write up 1 January 2018 – 31 March 2018 ( 3 months) 
 
Appendix 
1. Data collection sheet 
2. Informed Consent document 
3. Assent document 
4. Hair collection guidelines 
5. Synopsis 
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Appendix B: Informed consent English version 
Part I: Informed Consent form for parents and guardians 
A prospective study to assess the value of mass spectrometry in the management of paediatric 
poisoning 
 
Your child is invited to participate in research aimed at identifying causes of unintended poisoning 
in children as well as finding better methods for testing children who come to hospital with signs 
and symptoms of unknown causes that could be due to poisoning. 
 
Children are curious by nature. As a result, they are prone to accidents including, exposure to 
household substances and medications. Exposure to medicines or household products in a child 
may result in them falling sick. A number of times it is not clear what the child was exposed to. 
Often, poisoning in children is only suspected by health care givers if the guardian/parent 
suspects it, or if the signs and symptoms the child has are suggestive. In both instances the cause 
itself is usually unknown. 
 
Our research aims to identify causes of poisoning in children admitted to the Red Cross War 
Memorial Children’s Hospital. The study also aims to find out whether the use of a test called 
Mass Spectrometry could be useful in the treatment of children coming to hospital with signs and 
symptoms suggestive of poisoning.  
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We can confirm whether or not your child was exposed to a potential poison by sending urine or 
blood samples from your child for testing with Mass Spectrometry. This is not a test that we 
usually do, although it has been used in other hospitals outside of Africa. 
 
All children that present to Red Cross War Memorial Children’s Hospital with any of the following 
problem can participate in this research: 
 
1. Confirmed or suspected recent poisoning 
2. Unexplained mental signs such as drowsiness, confusion, irritability and unexplained fits 
3. Unexplained or unusual forms of diarrhoea and vomiting  
4. Unexplained blood tests that may show problems with the kidneys, liver or other organs 
 
You and your child may choose to participate in this research or not. Your child will receive the 
usual care as per our protocols whether or not you choose to participate in this study. The study 
does not change the treatment that your child receives. However, if you decide to take part in the 
study and Mass Spectrometry identifies a possible poison that needs treatment or further referral 
your child may be able to benefit from this. 
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Study investigations 
Your child will have extra tests done which will be sent for mass spectrometry: 
• A small amount of blood (about a teaspoonful) will be collected in addition to the usual 
tests 
• A small amount of urine  
• Depending on the symptoms, a snippet of hair may be collected 
With your permission some or all of leftover specimens will be stored for future tests 
After discharge you and your family will be contacted via a phone call within 3 weeks to inform 
you of any results as well as further management if it is required. 
 
Side Effects and risks 
To minimise physical trauma and distress to the child, blood and urine sample collection will be 
done at the same time as the routine tests that your child will be having.  
 
Benefits 
If your child participates in this research, your child will have the benefit of extra tests to look for 
the cause of the illness he/she came in with. This may improve treatment as it may indicate a 
specific poison or drug that may need specific treatment. 
 
Reimbursements 
The research will not cost you anything. You will not be given any money or gifts to take part in 
this research. 
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Confidentiality 
The information that we collect from this study will be kept confidential. Any study information 
about you and your child will have a number on it instead of a name. Only the researchers will 
know what your child’s number is. However, there is a small risk that someone may identify your 
child, but this is unlikely to happen 
 
What will happen to the information collected? 
What we learn from this research will be used to make recommendations on how best to treat 
children who come in with suspected poisoning. It will be shared with other health care workers. 
The identity of your child will be kept confidential throughout. 
 
Withdrawal from the study 
You may choose to withdraw from the study at any time and your child will still receive the same 
treatment they are meant to receive.  
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Who to Contact 
If you have any questions you may ask them now or later, even after the study has started. If you 
wish to ask questions later, you may contact the following: 
Dr Norbertta Washaya 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road 
Rondebosch, 7700 




Dr Heloise Buys 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road 
Rondebosch, 7700 
Tel: 021 658 5111 E-mail: Heloise.buys@uct.ac.za 
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This proposal has been reviewed and approved by the Human Research Ethics Committee of 
the University of Cape Town, which is a committee whose task it is to make sure that research 
participants are protected from harm.  If you wish to find about more about the ethics 
committee, contact  
Mrs Lamees Emjedi 
Research Ethics Committee 
E 52 Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone: +27 21 406 6338 
Fax: 27 21 406 6411  
Email: nosi.tsama@uct.ac.za  and shuretta.thomas@uct.ac.za 
 
Print Name of Parent/Guardian_______________________________________ 
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Part II: Certificate of Consent for the storage of samples 
The samples will be stored by the UCT Clinical Pharmacology division at Groote Schuur Hospital, 
who will be the primary custodians. The value of storage of the samples is that better research 
methods may become available in the future. We can then use the same samples to analyse these 
methods and so help improve the care of more children in the future. 
 
Storage of samples 
 
If any of the blood or urine or hair samples my child has provided for this research project is 
unused or leftover when the project is completed: 
 
I give my permission for my child’s blood/urine/hair (circle what applies) samples to be 
stored and used in future research of any type, which has been properly approved  
 
I give permission for my child’s blood/urine/hair (circle what applies) samples to be 
stored and used in future research but only for research in poisoning.  
 
I give permission for my child’s samples to be stored and used in future research  
     except for research about _________________________________ 
 
OR         
I wish my child’s samples to be destroyed immediately.  
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AND 
              I want my child’s identity to be removed from my child’s samples.  
 
  I want my child’s identity to be kept with my child’s samples. 
AND 
I wish my child’s specimens to be destroyed in the event of his/her death  
 
I give permission for the use of my child’s specimens even in the event of his/her death 
 
The stored samples will only be used for further research after approval from The Human 
Research Ethics Committee of the University of Cape Town, which is a committee whose task it 
is to make sure that research participants are protected from harm. Access will be limited to 
approved researchers. 
 
I have read the foregoing information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction.  I consent voluntarily for my child to participate in this study. 
 
Print Name of Parent/Guardian_______________________________________ 
 
Signature of Parent/Guardian ________________________________________ 
Date ________________________ 
Day/month/year    




A literate witness must sign (if possible, this person should be selected by the Parent/Guardian 
and should have no connection to the research team). Parents/Guardians who are illiterate 
should include their thumb-print as well.   
 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness__________________________ AND Thumbprint of Parent/Guardian 
Signature of witness ___________________________ 
Date ________________________ 
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Statement by the researcher/person taking consent 
 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
 
1. Blood collection 
2. Urine collection 
3. Hair collection 
4. Samples may be stored for possible future analysis. 
 
I confirm that the Parent/Guardian was given an opportunity to ask questions about the 
study, and all the questions asked by the Parent/Guardian have been answered correctly and to 
the best of my ability. I confirm that the Parent/Guardian has not been coerced into giving 
consent, and the consent has been given freely and voluntarily.  
 
A copy of this information and consent form has been provided to the Parent/Guardian. 
 
Name of Researcher/person taking the consent       _____________________________  
 
Signature of Researcher/person taking the consent _____________________________ 
 
Date ___________________________    
                 Day/month/year 
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Appendix C: Informed consent Afrikaans version 
 Deel i: Ingeligte Toestemming Vorm Vir Ouers En Voogde 
'n Vooruitsigtige studie om die waarde te bepaal van Massaspektrometrie in die behandeling 
van pediatriese vergiftiging 
 
Jou kind is genooi om deel te neem aan navorsing gemik op die identifisering van oorsake van 
onbedoelde vergiftiging in kinders. Ons wil ook daardeur beter metodes vind vir toetse in kinders 
wat na die hospitaal toe kom met tekens en simptome van onbekende oorsake, wat dalk as 
gevolg van vergiftiging kan wees. 
 
Kinders is nuuskierig deur die natuur. Gevolglik is hulle geneig tot ongelukke, insluitend 
blootstelling aan huishoudelike stowwe en medikasie. Blootstelling aan medisyne of 
huishoudelike produkte in 'n kind mag hulle siek maak. Partykeer  is dit nie duidelik wat die kind 
aan blootgestel is nie. Dikwels kan vergiftiging in kinders slegs vermoed word deur 
gesondheidsorg versorgers as die voog/ouer vermoed dit noem, of daar tekens en simptome is 
daarvan. In albei gevalle is die oorsaak gewoonlik onbekend. 
 
Ons navorsing se doel is om die oorsake van vergiftigings van kinders wat by Rooi Kruis hospitaal 
opgeneem word te identifiseer. Die studie se doel is ook om vas te stel of die gebruik van 'n toets, 
naamlik ”Massaspektrometrie”  nut het in die behandeling van kinders in die hospitaal met 
tekens en simptome van vergiftiging in die toekoms.  
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Ons kan bevestig of jou kind blootgestel is aan 'n potensiale  gif deur urine of bloed monsters van 
jou kind te stuur vir toetse met Massaspektrometrie. Dit is nie 'n toets wat ons gewoonlik doen 
nie, alhoewel dit in gebruik is in ander hospitale buite Afrika. 
 
Alle kinders wat Rooikruis Hospitaal toe kom met enige van die volgende probleme kan deelneem 
aan hierdie navorsing: 
1. Bevestigde of vermoedelike onlangse vergiftiging 
2. Onverklaarbare geestelike tekens soos lomerigheid, verwarring, prikkelbaarheid en 
onverklaarbare pas 
3. Onverklaarbare of ongewone vorms van diarree en braking 
4. Onverklaarbare bloed toetse wat probleme met die niere, lewer en ander organe kan wys 
 
Jy en jou kind kan kies om aan hierdie navorsing deelteneem of nie. Jou kind sal die gewone sorg 
kry wat ons protokolle aanbied, al kies jy nie om deel te neem aan hierdie studie nie. Die studie 
verander nie die behandeling wat u kind ontvang nie. Egter, as jy besluit om deel te neem aan die 
studie en massaspektrometrie identifiseer 'n moontlike gif wat moet behandel word kan jou kind 
dalk ‘n voordeel hieruit kry. 
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Studie Ondersoeke 
Jou kind sal ekstra toetse kry  wat gestuur sal word vir Massaspektrometrie: 
• ‘N klein hoeveelheid bloed (oor 'n teelepelvol) sal versamel word bykomend tot die 
gewone toetse 
• 'N klein hoeveelheid urine 
• Afhangende van die simptome, mag 'n stukkie hare versamel word 
 
Met jou toestemming sal sommige of al die oorskiet monsters gestoor word vir toekomstige 
toetse 
 
Na ontslag sal jy en jou gesin gekontak word deur ‘n foon oproep binne 3 weke, met inlig van 
enige resultate, asook verdere behandeling indien dit nodig is. 
 
Newe-effekte en risiko's 
Om fisiese trauma end nood aan jou kind te minimaliseer, sal bloed- en urine- monster 
versameling terselfdetyd gedoen word as die roetine toetse wat jou kind sal kry.  
 
Voordele 
As jou kind deelneem aan hierdie navorsing, sal jou kind die voordeel van ekstra toetse kry wat 
ook kyk vir die oorsaak van die siekte wat hy/sy het. Dit mag behandeling verbeter as dit aandui 
op 'n spesifieke gif of dwelm wat spesifieke behandeling het. 
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Vergoeding 
Die navorsing sal nie geld kos nie. Jy sal nie enige geld gegee word nie en geen geskenke kry om 
aan hierdie navorsing deel te neem nie. 
 
Vertroulikheid 
Die inligting wat ons insamel in hierdie studie sal vertroulik behou word. Enige studie inligting oor 
jou en jou kind sal net 'n nommer op dit he, in plaas van 'n naam. Slegs die navorsers sal weet wat 
jou kind se nommer is. Daar is 'n klein risiko dat iemand jou kind kan identifiseer, maar dit is 
onwaarskynlik dat dit sal gebeur. 
 
Wat sal gebeur met die inligting wat versamel is? 
Wat ons leer uit hierdie navorsing sal gebruik word om aanbevelings te doen oor hoe beste 
kinders  te behandel kinders wat inkom met vermoedelike vergiftiging. Die navorsing sal gedeel 
word met ander gesondheidsorg werkers. Die identiteit van jou kind word regdeur vertroulik 
behou. 
 
Onttrekking van die studie  
Jy kan enige tyd kies om te onttrek van die studie en jou kind sal steeds die dieselfde behandeling 
wat hulle veronderstel is om te ontvang  kry.  
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Wie om te kontak 
As jy enige vrae het mag jy hulle nou vra, of later, selfs nadat die studie begin het. As jy later wil 
vrae vrae kan jy die volgende kontak: 
Dr Norbertta Washaya 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road 
Rondebosch, 7700 




Dr Heloise Buys 
Red Cross War Memorial Children’s Hospital 
Klipfontein Road 
Rondebosch, 7700 
Tel: 021 658 5111 E-mail: Heloise.buys@uct.ac.za 
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Hierdie voorstel is hersien en goedgekeur deur die Menslike Navorsing Etiese Komitee 
van die Universiteit van Kaapstad, wat 'n komitee is wie se taak dit is om te sorg dat 
navorsing deelnemers teen skade beskerm word.  As jy meer wil uitvind oor die etiese 
komitee, kontak: 
 
Mrs Lamees Emjedi 
Research Ethics Committee 
E 52 Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone: +27 21 406 6338 
Fax: 27 21 406 6411  




Naam Van Ouer/Voog In Drukskrif _______________________________________ 
 
 




             Dag/maand/jaar 
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Deel II: Sertifikaat Van Toestemming Vir Die Stoor Van Monsters 
 
Die monsters sal bewaar word deur die UK kliniese Farmakologie afdeling by Groote Schuur 
Hospitaal, wat die primêre bewaarders sal wees. Die waarde van die stoor van die monsters is dat 
beter navorsing metodes in die toekoms beskikbaar kan word. Ons kan dan die dieselfde 
monsters gebruik om te ontleed met hierdie metodes en so help om die behandeling  van meer 




Stoor van monsters 
 
Indien enige van die bloed of urine of hare monsters van my kind vir hierdie navorsing projek 
ongebruikte is, of daar oorskiet wanneer die projek voltooi is: 
 
  Ek gee toestemming vir my kind se bloed/urine/hare (sirkel wat geld) monsters om 
gestoor en gebruik te word in toekomstige  navorsing van enige tipe, wat die nodige 
goedkeuring het 
 
 Ek gee toestemming vir my kind se bloed/urine/hare (sirkel wat geld) monsters om 
gestoor en gebruik te word in toekomstige  navorsing, maar net vir navorsing in 
vergiftiging.  
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  Ek gee toestemming vir my kind se monster om gestoor te word en gebruik te word in 
toekomstige navorsing , maar nie vir navorsing 
oor:_________________________________ 
 
OF         
 Ek wil my kind se monsters onmiddellik vernietig laat word.  
 
EN 
              Ek wil my kind se identiteit verwyder he van my kind se monsters.  
 
  Ek wil my kind se identiteit behou met my kind se monsters. 
EN 
 Ek wil my kind se monsters vernietig he in die geval van sy/haar dood  
 
  Ek gee toestemming vir die gebruik van my kind se monsters selfs in die geval van sy/haar 
dood 
 
Die gestoorde monsters sal slegs gebruik word vir verdere navorsing na goedkeuring van die 
Menslike Navorsing Etiese Komitee van die Universiteit van Kaapstad, wat 'n komitee is wie se 
taak dit is om te sorg dat navorsing deelnemers teen skade beskerm word. Toegang sal beperk 
word tot navorsers wat goedgekeur is. 
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Ek het die voorafgaande inligting gelees, of dit was vir my gelees. Ek het die geleentheid gehad 
om vrae te vra oor dit en enige vrae wat ek gevra het was tot my bevrediging beantwoord.  Ek gee 
vrywillig toestemming vir my kind om deel te neem aan hierdie studie. 
 
Naam van ouer/voog in drukskrif _______________________________________ 
Handtekening van ouer/voog ________________________________________ 
Datum ________________________ 
Dag/maand/jaar   
 
As ongeletterde 
'n Geletterd wat getuie was moet teken (indien moontlik, moet hierdie persoon gekies word deur 
die ouer/voog en moet geen verbinding met die navorsing span he nie). Ouers/voogde wat 
ongeletterd is  moet hul duim-print ook insluit.   
 
Ek het die akkurate lees van die toestemmings vorm vir die potensiële deelnemer gesien, en die 
individu het die geleentheid gehad om vrae te vra. Ek bevestig dat die individu vrylik toestemming 
gegee het.  
 
Naam van getuie in drukskrif __________________________ EN Duim  van ouer/voog 
 Handtekening van getuie ___________________________ 
Datum ________________________ 
              Dag/maand/jaar 
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Verklaring deur die navorser/persoon wat toestemming neem 
 
Verklaring deur die navorser/person wat toestemming neem: 
 
1. Bloed versameling  
2. Urine versameling 
3. Hare versameling 
4. Monsters kan bewaar word vir moontlike toekomstige analise. 
 
Ek bevestig dat die ouer/voog 'n geleentheid gegee was om vrae te vra oor die studie, en dat al 
die vrae korrek beantwoord is, en na die beste van my vermoë. Ek bevestig dat die individu nie 
gedwing is om hierdie toestemming te gee nie, en dat die toestemming vrywillig gegee is. 
 
'N afskrif van hierdie inligting en toestemmings vorm is aan die ouer/voog voorsien. 
 
Naam van navorser/person wat die toestemming neem _____________________________  
    




Datum ___________________________   
             Dag/maand/jaar     
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Appendix D: Assent English version 
Patient information and assent form for children older than seven years 
Utility of Mass Spectrometry in paediatric poisoning 
 
You are invited to take part in a study that is being done at this hospital. Please read this 
information and ask the study staff or doctor any questions you may have. 
Background  
You are in hospital because it is suspected that you may have come in to contact with a 
medication or poison, or maybe you have not, but the way you are feeling and the tests we have 
done make us think you may have come in to contact with some medicine or poison. 
 
We can find out if you have some medicine or poison in your body by sending urine and/or blood 
samples from you for a special test called Mass Spectrometry. This is not a test that we normally 
do. But, we would like to know the causes of poisoning in children admitted to The Red Cross War 
Memorial Children’s Hospital, as well as to see if this special test would be helpful in helping 
other children who will come to hospital in the future 
 
What will happen to you if you agree to take part in the research? 
If you agree to take part, then the following tests will be done to check for the presence of any 
poison or medicine in your body 
• A small amount of blood (about a teaspoon full) will be taken from you  
• We will ask you for a small amount of urine 
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• We may ask for a small piece of your hair 
How will it help you to take part in the study? 
If you agree to take part in the study we will be able to tell if you are not feeling well because of a 
medicine or poison in your body. However even if you choose not to have these tests done you 
will still be treated the way that you are supposed to, it will not change how you are taken care 
of. 
 
Will the study hurt or make you feel bad? 
You will feel some pain from the needle when blood is taken. We will put some special cream on 
you to make it less sore.  
 
Do you have to be in the study? 
Your parent/legal guardian has said it is fine for you to be in the study, but you can still make up 
your own mind and do not have to take part if you don’t want to. Nobody will be angry or upset 
with you if you don’t want to take part. 
 
What do I do if I have any questions? 
If you have any questions about this study, you can ask your parent/legal guardian or the study 
staff or doctor any questions.  
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I have read and understood this form. My questions have been answered.  I am willing to take 
part in this study.  
 
I, ______________________________________ agree to take part in this study. 
 
Signed:  __________________ Witness:  __________________________ 
 
Date:   ___________________ Date:     __________________________ 





I have witnessed the accurate reading of the assent form to the child, and the child has had the 
opportunity to ask questions. I confirm that the child has given consent freely.  
 
Print name of witness (not a parent)_____________________  AND Thumb print of child. 
Signature of witness ______________________ 
Date ________________________ 
             Day/month/year      
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Statement by the researcher/person taking consent 
 
I have accurately read out the information sheet to the potential participant, and to the best of my 
ability made sure that the child understands that the following will be done: 
1. Urine specimen 
2. Blood specimen 
3. Maybe a piece of hair 
 
I confirm that the child was given an opportunity to ask questions about the study, and all 
the questions asked by him/her have been answered correctly and to the best of my ability. I 
confirm that the individual has not been coerced into giving consent, and the consent has been 
given freely and voluntarily.  
   
 A copy of this assent form has been provided to the participant. 
 
Print Name of Researcher/person taking the assent________________________   
  
Signature of Researcher /person taking the assent __________________________ 
 
 
Date ___________________________    
                 Day/month/year 
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Appendix E: Assent Afrikaans version 
Pasiënt inligting en bekragtigings vorm vir kinders ouer as sewe jaar 
Nut van Massaspektrometrie in pediatriese vergiftiging 
 
Jy word uitgenooi om deel te neem aan 'n studie wat by hierdie hospitaal gedoen word. Lees 
asseblief hierdie inligting en vra die studie personeel of dokter enige vrae wat jy het. 
Agtergrond  
Jy is in die hospitaal opgeneem omdat dit vermoed is dat jy in kontak was met 'n medikasie of gif, 
of jy was dalk nie, maar die manier waarop jy voel en die toetse laat ons dink jy was in kontak met 
sekere medisyne of gif. 
 
Ons kan uitvind of jy medisyne of vergiftiging in jou liggaam het deur urine en/of bloed toetse van 
jou te stuur vir 'n spesiale toets – dit word “Massaspektrometrie” genoem. Dit is nie 'n toets wat 
ons normaalweg doen nie, maar ons wil graag weet wat die oorsake van vergiftigings is in kinders 
in Rooi Kruis Hospitaal, sowel as om te sien of hierdie spesiale toets ander kinders ook kan help 
wat in die toekoms na die hospitaal toe sal kom. 
 
Wat sal gebeur as jy instem om deel te neem aan die navorsing? 
As jy instem om deel te neem, dan sal die volgende toetse gedoen word om te kyk vir die 
teenwoordigheid van enige gif of medisyne in jou liggaam: 
• 'n Klein hoeveelheid bloed (ongeveer 'n teelepel vol) sal van jou geneem word 
• Ons sal jou vra vir 'n klein hoeveelheid urine 
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• Ons kan jou vra vir 'n stukkie van jou hare 
 
Hoe sal dit jou help om aan die studie deel te neem? 
As jy instem om deel te neem in die studie sal ons in weet of jy siek gevoel het as gevolg van 'n 
medisyne of gif wat jou liggaam was. Selfs as jy kies om nie hierdie toetse te doen nie sal jy nog 
behandel word op die manier wat jy veronderstel is om te wees, dit sal nie verander hoe jy 
versorg word nie. 
 
Sal die studie seermaak of maak laat jy sleg voel? 
Jy sal 'n bietjie pyn van die naald voel wanneer bloed geneem word. Ons sal 'n spesiale room 
aansmeer voor die bloed geneem word om dit minder seer te maak. 
 
Hoef ek in hierdie studie te wees? 
Jou ouer/wettige voog het gesê dit is goed vir jou om in die studie te wees, maar jy kan steeds jou 
eie besluit neem om nie deel te neem nie, as jy nie wil nie. Niemand sal kwaad word of met jou 
ontsteld wees as jy nie wil deel neem nie. 
 
Wat doen ek as ek enige vrae het? 
As jy enige vrae het oor hierdie studie, kan jy jou ouer/wettige voog vra, of vra die studie 
personeel of dokter enige vrae. 
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Ek het gelees en verstaan hierdie vorm. My vrae is beantwoord.  Ek is bereid om deel te neem in 
hierdie studie.  
 
Ek, ______________________________________ stem in om deel te neem in hierdie studie. 
Onderteken:  __________________ Getuie:  __________________________ 
 
Datum:   ___________________ Datum:     __________________________ 
   Dag/maand/jaar 
As ongeletterde: 
 
Ek het die akkurate lees van die bekragtigings vorm aan die kind gesien, en die kind het die 
geleentheid gehad om vrae te vra. Ek bevestig dat die kind vrywillig  toestemming gegee het.  
 
Naam van getuie (nie 'n ouer) in drukskrif_____________________  EN duim druk van kind. 
Handtekening van getuie ______________________ 
Datum ________________________ 
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Verklaring deur die navorser/persoon wat toestemming neem 
 
Ek het noukeurig gelees uit die INLIGTINGSBLAD vir die potensiële deelnemer, en het na die beste 
van my vermoë seker gemaak dat die kind verstaan dat die volgende gedoen sal word: 
1. urine monster  
2. bloed monster  
3. miskien 'n stukkie hare 
 
Ek bevestig dat die kind 'n geleentheid gegee was om vrae te vra oor die studie, en dat al die vrae 
korrek beantwoord is, na die beste van my vermoë. Ek bevestig dat die individu nie gedwing is om 
hierdie toestemming te gee nie, en dat die toestemming vrywillig gegee is.  
   
 'n Afskrif van hierdie bekragtig vorm is voorsien vir die deelnemer. 
 
Naam van navorser/persoon wat bekragtig neem in drukskrif ________________________ 
    
Handtekening van navorser /persoon wat bekragting neem __________________________ 
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Appendix F: Data collection tool 
Value of Mass Spectrometry in Paediatric Poisoning Data Collection Sheet 
 
A.  Demographic Data 
Date of Birth      Sex: Male□  Female□ 
Address:             
             
           
Primary caregiver: Mother □  Father □  Grandmother □ Other (specify) _____  
Historian: Patient □  Mother □ Father □ Neighbour □  Other (specify) _____ 
Type of housing: Formal □ Informal □ Number of Occupants:     
Attends Crèche:  Yes □  No □ 
B.  Anthropometry 
Weight:   ___kg 
  
C.  Child survival 
IUTD/INUTD  RVD unexposed rapid -ve / RVD Exposed Rapid or  -ve/ RVD exposed rapid 
or PCR +ve 
D. TOXIN EXPOSURE 
Suspicion of poisoning from: History □ Examination □ Investigations □ 
Witnessed Toxin ingestion:   Yes □ No □ 
Toxin in the home:   Yes □ No □ 
Toxin in the street: Yes □ No □ 
Toxin known:   Yes □  No □ 
Toxin name:  ______________________ 
Time and date exposed: 
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Home remedy given: 
_______________________________________________________________________________
__________ 






E. Clinical Details 
 Date of Admission:     Time of admission:      
Referred: Regional Hospital/District Hospital/Day Hospital /CHC/Self 
Presenting complaint            
             
             
             
             
     ______________________________ 
Clinical Features 
Scoring: done at admission and during admission/ done retrospectively 
Central Nervous System Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & spontaneously 
resolving symptoms or signs 
Pronounced or prolonged 
symptoms or signs 





Unconsciousness with appropriate 
response to pain  
Deep coma with 
inappropriate response 
to pain or unresponsive 
to pain 
Mild extrapyramidal symptoms  Brief apnoea/bradypnoea  Respiratory depression 





Extreme agitation  




Mild visual disturbances/auditory 
disturbances 
Pronounced extrapyramidal 
symptoms   
epilepticus/opisthotonus  
 Pronounced  
cholinergic/anticholinergic 
symptoms  
Generalized  paralysis or 
paralysis affecting vital 
functions  
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 Localized paralysis not affecting 
vital functions  
Blindness 
 Visual/ auditory disturbances  deafness 
 
Central Nervous System Other: 
a) Level of consciousness E   M  V  Total 
A  V  P  U 
b) Hyperactive  Yes □ No □ 
c) abnormal movements Yes □ No □ 
d) nystagmus  Yes □ No □ 
e) photophobia  Yes □ No □ 
f) hallucinations  Yes □ No □ 
g) dystonia  Yes □ No □ 
h) muscle weakness Yes □ No □ 
i) pin point pupil s Yes □ No □ 
j) dilated pupils  Yes □ No □ 
k) other pupil defect Yes □ No □   Specify ____________________ 
 
GIT Poisoning severity score: 
None Minor Moderate Severe 





Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
Vomiting/diarrhoea/pain/ 
Irritation/ 1st degree burns/ 








 1st degree burns of critical 
localization/ 2nd & 3rd degree 
burns in restricted areas 
Dysphagia 
Endoscopy: ulcerative trans 
mucosal lesions 
More wide spread 2nd &3rd 








a) nausea   Yes □ No □ 
b) jaundice  Yes □ No □ 
c) hepatomegaly  Yes □ No □ 
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Respiratory System Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
Irritation/ coughing/ 
breathlessness/  mild 




stridor/ hypoxemia requiring 
extra oxygen  
 
Manifest respiratory 












Chest X-ray: abnormal with 
minor or no symptoms  
 
Chest X-ray: abnormal with 
moderate symptoms  
 
 
Chest X-ray: abnormal 
with severe symptoms 
 
Respiratory system Other 
a) tachypnoea  Yes □ No □   RR ____________BPM_ 
b) depressed effort Yes □ No □ 
c) increased secretions Yes □ No □ 





109 | P a g e  
 
Cardiovascular System Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged symptoms or 
signs 
Severe or life threatening 
symptoms or signs 
 Isolated extrasystoles  
Mild and transient 
hypo/hypertension  
 
Sinus bradycardia (HR ~40-50 in adults, 
60-80 in infants and children, 80-90 in 
neonates) / 
 Sinus tachycardia (HR ~140-180 in 
adults, 160-190 in infants and children, 
160-200 in neonates) / 
 Frequent extrasystoles, atrial 
fibrillation/flutter/ AV-block I-II, 
prolonged QRS and QTc-
time/repolarization abnormalities  
Myocardial ischaemia 
 More pronounced hypo/hypertension  
Severe sinus bradycardia (HR 
~<40 in adults, <60 in infants and 
children, <80 in neonates)/   
Severe sinus tachycardia (HR 
~>180 in adults, >190 in infants 
and children, >200 in neonates)/  
 Life-threatening ventricular 
dysrhythmias/ AV block III, 
asystole  
 Myocardial infarction  
 Shock/hypertensive crisis 
 
Cardiovascular system other: 
BP systolic:     BP diastolic:    Mean BP   
  HR:  ____BPM  
Metabolic System Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Mild acid-base 
disturbances  (HCO3 ~15-




• Mild electrolyte and 
fluid disturbances (K+ 
3.0-3.4 or 5.2-5.9 mmol/l)  
  
• Mild hypoglycaemia 
(~50-70 mg/dl or 2.8-3.9 
mmol/l in adults)  
  
• Hyperthermia of short 
duration  
More pronounced acid-
base disturbances (HCO3 
~10-14 or >40 mmol/l; pH 
~7.15-7.24 or 7.60-7.69)  
 More pronounced 
electrolyte and fluid 
disturbances (K+ 2.5-2.9 
or 6.0-6.9 mmol/l)  
More pronounced 
hypoglycaemia (~3050 
mg/dl or 1.7-2.8 mmol/l in 
adults)  
Hyperthermia of longer 
duration 
Severe acid-base 
disturbances (HCO3 ~<10  
mmol/l; pH ~<7.15 or 
>7.7)  
Severe electrolyte and 
fluid disturbances         (K+ 
<2.5 or >7.0 mmol/l)  
 Severe hypoglycaemia 
(~<30 mg/dl or        1.7 
mmol/l in adults)  
Dangerous hypo- or 
hyperthermia 
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symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Minimal rise in serum 
enzymes (AST, ALT ~2-5 x 
normal)   
 
Rise in serum enzymes 
(AST, ALT ~5-50 x normal) 
but no diagnostic 
biochemical (e.g. 
ammonia, clotting factors) 
or clinical evidence of liver 
dysfunction 
Rise in serum enzymes 
(~>50 x normal) or 
biochemical (e.g. 
ammonia, clotting 
factors) or clinical 
evidence of liver failure 
 • Hyperthermia of short 
duration  




Kidney Poisoning severity score: 
None Minor Moderate Severe 






symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Minimal proteinuria / 
haematuria 




   Renal dysfunction (e.g. 
oliguria, polyuria, serum 
creatinine of ~200-500 
µmol/l) 
Renal failure (e.g. anuria  
/   serum creatinine of 
>500 µmol/l) 
 
16. Renal other 
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Blood Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Mild haemolysis  Haemolysis  Massive haemolysis  
  Mild 
methaemoglobinemia        
(metHb ~10-30%) 
 More pronounced 
methaemoglobinemia 
(metHb ~30-50%)  
 
 Severe 
methaemoglobinemia        
(metHb >50%)  
 












Muscular Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Mild pain, tenderness/ Pain, rigidity, cramping 
and fasciculation/ 
Rhabdomyolysis,  






 CPK ~250-1,500 iu/l CPK ~1,500-10,000 iu/l ,  CPK ~>10,000 iu/l / 
Compartment syndrome 
Local effects on skin Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Irritation, 1st degree 
burns (reddening) or 2nd 
degree burns in <10% of 
body surface area 
2 nd degree burns in 10-
50% of body surface 
(children: 10-30%) or 3rd 
2 nd degree burns in 
>50% of body surface 
(children: >30%) or 3rd 
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degree burns in <2% of 
body surface area 
degree burns in >2% of 
body surface area 
 
Skin Other  
General 
a) Fever    Yes □ No □ 
b) Hypothermia  Yes □ No □ 
c) Sweating  Yes □ No □ 
d) Flushed skin  Yes □ No □ 
e) Dry mouth  Yes □ No □ 
f) Hyper-salivation  Yes □ No □ 
g) Skin bruising  Yes □ No □ 
h) Petechiae/ purpura Yes □ No □ 
i) Epistaxis  Yes □ No □ 
j) Dehydrated  Yes □ No □ 
a. If yes level of dehydration  Shock/ Severe / Some  
Local effects on eye Poisoning severity score: 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or 
prolonged symptoms or 
signs 
Severe or life threatening 
symptoms or signs 




corneal abrasion/ Minor 
(punctate) corneal 
ulcers 




Local effects from bites and stings 
None Minor Moderate Severe 




Mild, transient & 
spontaneously resolving 
symptoms or signs 
Pronounced or prolonged 
symptoms or signs 
Severe or life threatening 
symptoms or signs 
 Local swelling, itching 
/Mild pain 
Swelling involving the 
whole extremity/ local 
necrosis/Moderate pain 
Swelling involving the 
whole extremity and 
significant parts of 
adjacent area, more 
extensive necrosis 
/Critical localization of 
swelling threatening the 
airways/Extreme pain 
17. Other clinical features (Specify) 
_______________________________________________________________ 










    
Na+     
K+     
Urea     
Creatinine     
Ca+     
Mg+     
PO42-     
Ammonia     
ALT     
AST     
GGT     
ALP     
TSB     
CBIL     
Albumin     
Total Prot     
pH     
BE     
HCO3     
pCO2     
pO2     
Glucose     
Lactate     
INR     
PT     
Fibrinogen     
G. Toxicology 
17. SureSlip/POC test result (Immunoassay) 
DONE  Yes □ No □ 
Date and time   ___________________________ 
Result __________________________________________________________________ 
18. NHLS Toxicology test  
Date & time test done     ___________ 
        Date & time result available        
 Result _________________________________________________________________ 
19. Mass spectrometry Urine 
Date & time test done     ___________ 
        Date & time result available        
 Result  







Mass spectrometry blood 
Date & time test done ___________ 
        Date & time result available        







Mass spectrometry Hair 
Date & time test done ___________ 




20. Admitted □   Not admitted □ 
21. Admission ward: Short stay ward □  High Care □ 
Ward Floor □  PICU □ 
22. IV Fluids: Yes □ No □ 
Bolus required  Yes □ No □ 
23. Inotropes:  Yes □ No □ 
24. Respiratory Support: Yes □ No □ 
a) Nasal prongs □  b)HFNC □ c) CPAP □ d)IPPV □ 
25. Anticonvulsants: Yes □ No □ 
a) Lorazepam□ b) phenobarbitone □ c) phenytoin □  d) Other  ______ 
26. Required resuscitation: Yes □ No □ 
27. Antidote given: Yes □ No □       If yes specify    __________________ 
28. Antidote given on:  Basis of history  □ 
     Basis of examination □ 
     Basis of investigation □ 
29. Date and Time antidote was administered ____________ 
 
I. Outcome 
30. Initial Diagnosis      ____________________________________ 
31. Final Diagnosis      ____________________________________ 
32. Died □ Discharged □ 
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33. Date of death / discharge __________________________ 
J. Social services referral 
In-patient referral:  Yes □ No □ 
Community SS referral: Yes □ No □ 
Form 22 completed Yes □ No □    Unknown  □ 
Specific SS intervention: 
1. education 
2. home visit 
3. surveillance 
4. removal and emergency placement order 
35. Follow up required: Yes □ No □ 
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Appendix G: Proposed protocol for use of LC-MS/MS at RCWMCH  
Who can order the test? 
Due to the cost of the test each test must be approved by the consultant on cover 
 
Indications 
• Unexplained acute neurological symptoms not due to trauma or infection 
• Known toxin or substance ingestion but with inconsistent clinical picture  
• Exposure or ingestion to an unknown/unidentifiable toxin or substance 
• First onset episode of psychosis not due to infection 
• Confirming positive point of care urine drug screen  
• Unexplained multiorgan failure 
Relative indications 
• History of drug abuse in family with supporting clinical symptoms 
Not useful 
• Known toxin or substance ingestion with consistent clinical picture 
What to include on the LC-MS/MS request form 
• Any medicines or drugs given at home or in hospital as part of therapy 
• Name of suspected toxin or drug 
Reference 
Norbertta Washaya, Alicia Evans, Rudzani Muloiwa et al. A Prospective Study to Assess the Value of Liquid 
Chromatography-Tandem Mass Spectrometry in the Management of Paediatric Poisoning at Red Cross 
War Memorial Children’s Hospital, Cape Town, South Africa, 22 July 2020, PREPRINT (Version 1) available 
at Research Square [https://doi.org/10.21203/rs.3.rs-45295/v  
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Appendix H: BMC Pediatrics journal reviewer comments and rebuttal  
 
Rebuttal document: BPED-D-20-01221 
A prospective study to assess the value of liquid chromatography-tandem mass spectrometry in the 
management of paediatric poisoning at Red Cross War Memorial Children’s Hospital, Cape Town, South 
Africa 
Norbertta Washaya; Alicia Evans; Rudzani Muloiwa; Peter Smith; Heloise Buys 
 
Reviewer 1  
 
119 | P a g e  
 
 
Reviewer 1 Comments Responses to reviewer comments 
 Comment 
The manuscript submitted by 
Washaya et al. evaluates the use of 
the LC-MS/MS methodology in the 
detection of intoxicants in children 
entering the emergency room with 
a suspected intoxication. 
 
The method described is potentially 
very useful especially, as the 
authors underline, in cases where 
the intoxicating substance is not 
known. Identification of the 
substance would be of great help in 
guiding therapy and the eventual 
administration of antidotes. 
Nevertheless, the manuscript needs 
to be modified and integrated 
under certain aspects. 
 
Thank you for your kind words. The manuscript has been 
revised and amendments been made to address the issues 
raised by the reviewer. 
   
 METHODS Page, 
lines 
 
1.  It is not specified by which 
criteria tests were done on 




















Thank you very much for the question. The study 
aimed to test for substances on a urine specimen 
and only opportunistically took a blood specimen. 
Patients were not bled solely for the purposes of the 
study. Only 6 patients did not have any urine 
samples and that was because the sample collected 
leaked.  
 
We have edited the text to clarify the above. The 
texts now read: 
 
 “A urine sample of eligible participants was sent to 
the laboratory for LC-MS/MS to establish the cause 
of poisoning. In addition, the attending clinician and 
laboratory were consulted for any leftover blood 
specimen after laboratory tests ordered by the 
attending clinician were completed that could 
likewise be tested on LC-MS/MS. Study participants 
were not bled solely for the study.” 
 
“A total of 146 (96%) urine samples from the 152 
study participants were analysed by LC-MS/MS after 
six samples were lost due to leakage in transit. For 
80(53%) participants, there was sufficient left-over 
blood specimen in the laboratory for LC-MS/MS 
testing. This included the six participants whose 
urine samples had been lost to leakage” 
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2.  Authors seem not to 
consider the half-life and 
elimination of the 
poisoning substances. I 
would not be surprised if 
some samples were 
negative because the toxic 
substance is eliminated via 
the bilio-fecal route, or if 
the time elapsed between 
the intake of the substance 
and the collection was not 
compatible with the half-



























Thank you very much for these valuable and valid 
points. We have considered these and agree that 
these points should have been reflected up in the 
discussion section as limitations of the study. We 
have made amendments that read: 
 
“It is possible that LC-MS/MS may have been limited 
by failure to detect substances that are eliminated 
via the hepatobiliary system which may not have 
been detectable in urine, as well as substances with 
a short half-life that may have degraded before 
sampling or analysis. These reasons are limitations of 
LC-MS/MS that the clinician needs to be aware of 
when utilising LC-MS/MS. All nine drugs that the LC-
MS/MS failed to identify, and yet were in the LC-
MS/MS library, are excreted in urine except for 
tenofovir, which is mainly excreted in faeces. A study 
done on sample stability indicated that substance 
degradation was dependent upon the type of 
substance and the temperature at which a sample is 
stored.” 
 
“The median turnaround time (TAT) for obtaining a 
result was 5 (IQR 3 – 7) days for urine LC-MS/MS and 
6 (IQR 4 -7) days for blood LC-MS/MS. A total of five 
patients had LC-MS/MS results within 24 hours.”  
 
“The median TAT for the 57, that were substance-
intake-likely cases and yet the LC-MS/MS was 
negative was 5 (IQR 3- 9) days for urine LC-MS/MS 
and 5(IQR 4 – 9) days for blood. TAT of the 71 
poisoning cases that had positive LC-MS/MS was 5 
(IQR 2 – 7) days for urine and 6 (IQR 4-7) days for 
blood.” 
3.  Moreover, since toxin is a 
poisonous substance that is 
a specific product of the 
metabolic activities of a 
living organism, this is not 
the right term to describe 
intoxicating substances all 
along the manuscript. 
Namely, bromazepam and 
diphenhydramine (lines 
214 and 215) are not 
toxins, so please find an 
adequate definition. 
 Thank you very much for bringing up this point.  We 
agree with your suggestion and we have changed 
the terminology from ‘toxin’ to ‘substance’ 
throughout the paper 




please clarify if the aim of 
the study is to describe the 
prevalence of LC-MS/MS, 
as written in the objective, 
or the value of LC-MS/MS, 








Thank you for raising this point. We agree that the 
title should be clearly aligned with the aim of the 
study. The title has been clarified. The title now 
reads: 
 
ThThe prevalence of liquid chromatography-tandem 
mass spectrometry confirmed paediatric poisoning 
at Red Cross War Memorial Children’s Hospital, Cape 
Town, South Africa” 
5.  No information is provided 
on the time elapsed 
between sampling and 
testing nor on how samples 
were stored. The reader 
may think that some 
samples may have tested 
negative due to 









































Thank you for noting the omission. LC-MS/MS was 
being used here as a research tool. As a result the 
samples were batched for testing. The turnaround 
time has been indicated and information on storage 
before testing has now been added to the methods 
section. 
 
The text now reads: 
 
“Due to the limited availability of the LC-MS/MS 
unit, samples were tested in batches. Once 
collected, samples were registered and transported 
to the laboratory where they were stored at 4 ºC 
until analysis. The median turnaround time (TAT) for 
obtaining a result was 5 (IQR 3 – 7) days for urine LC-
MS/MS and 6 (IQR 4 -7) days for blood LC-MS/MS. A 
total of five patients had LC-MS/MS results within 24 
hours. 
 
Trained personnel ran the samples and interpreted 
the results.  For quality control, internal standards 
were added to each sample as part of the sample 
preparation. Each run included blanks, as well as 
positive and negative controls to ensure accurate 
results.(29, 30)  
 
In order to observe for possible substance 
degradation, compound stability tests were done on 
the LC-MS/MS unit. A commercially obtained 
control, a system suitability test (SST) (Restek® 
Corporation) was run daily. The kit contains 8 
compounds of known concentrations. The peak 
areas of each compound were observed to confirm 
that the instrument performance and sensitivity 
were optimal and at the same time to observe for 
possible compound degradation, by comparing 
these areas to previously acquired data.” 
 
“The median turnaround time (TAT) for obtaining a 







result was 5 (IQR 3 – 7) days for urine LC-MS/MS and 
6 (IQR 4 -7) days for blood LC-MS/MS. A total of five 
patients had LC-MS/MS results within 24 hours.” 
 
“The median TAT for the 57, that were substance-
intake-likely cases and yet the LC-MS/MS was 
negative was 5 (IQR 3- 9) days for urine LC-MS/MS 
and 5(IQR 4 – 9) days for blood. TAT of the 71 
poisoning cases that had positive LC-MS/MS was 5 
(IQR 2 – 7) days for urine and 6(IQR 4-7) days for 
blood.” 
 
“A study done on sample stability indicated that 
substance degradation was dependent upon the 
type of substance and the temperature at which a 
sample is stored.(31) Substances stored at  25ºC, 4 
ºC and -20ºC were later extracted and analysed at 
15, 60 and 90 days and the average relative peaks on 
these days were compared with the average relative 
peaks at baseline.(31) The study concluded that the 
best temperature to store samples is -20ºC, although 
even at 4ºC the substances could still be detected 
even if the peaks were lower.(31)  The samples in 
our study were stored  at 4ºC, and therefore 
substance degradation cannot be ruled out.” 
6.  Line 
123-
125 
"The immunisation status 
was reviewed from the 
admission notes and/or the 
road to health card 
(immunisation status card) 
and noted as up to date if 
the child had received 
appropriate doses of 
vaccination for age as per 
the national immunisation 
schedule". What is the 
interest of this information 
in the context of the 
article? 
 
 Thank you for this question.  
We had intended to use health seeking behaviour as 
indicated by immunisation status as proxy tool for 
assessing the risk of poisoning. But we acknowledge 
your point and we realise that this statement may 
confuse readers and so we have removed it. 
7.  Line 
128 
"urine specimen and/or 
blood sample" on the basis 
of what one or the other? 
There is a lot of difference, 
just consider the 
elimination route or the 
time elapsed since 
assumption. 
 We have addressed this question in our response to 
reviewer comment 1. 
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patient classification (line 
143 and following) is not 
clear. Authors affirm that 
"The toxin-intake-unlikely 
group were patients whose 
clinical presentation could 
be explained by an 
alternative medical 
diagnosis and were, 
therefore, not considered 
poisoning cases." While 
when describing the 
participants, they state "All 
patients admitted at 
RCWMCH with suspected 
poisoning were eligible for 
recruitment into the 
study". Are therefore the 
toxin-intake-unlikely 













Thank you for the comment and request for 
clarification. The classification was done after 
analysis and not when participants were recruited. 
Patients were admitted as suspected poisoning 
cases. And once the authors had analysed the results 
and clinical presentations, the patients were 
classified into one of three groups, for the purposes 
of our study. The section has been amended to bring 
clarity to the classification used. The section now 
reads,  
 
“As poisoning is defined  by the presence of clinical 
(somatic and/or mental) manifestations, or 
laboratory and/or electrocardiographic 
abnormalities resulting from exposure to a 
substance that can lead to harmful clinical effects 
(31), once all the toxicology investigations and 
clinical presentations were analysed, the authors 
classified  the cases into one of three groups: 
substance-intake-unlikely, substance-intake-likely or 
substance-intake- unclear. The substance-intake-
unlikely group were patients whose clinical 
presentation could be explained by an alternative 
medical diagnosis and were, therefore, not 
considered poisoning cases even though they were 
admitted as cases of suspected poisoning. The 
substance-intake-unclear group were patients 
whose clinical presentation could not be explained 
by a medical diagnosis and whose toxicology 
investigation results were not indicative of 
poisoning. The substance-intake-likely group were 
those patients whose clinical presentation could be 
explained by a toxic substance (even in the absence 
of an LC-MS/MS identified substance) and were 
therefore considered poisoning cases, even in the 
absence of symptoms.” 
9.  The criteria for 




Thank you for this comment. We have addressed 







did you investigate the 
clinical history of the 
patients or if caregivers 
had any initiative to treat 
intoxication? Did you 
investigate if drugs 
detected by LC-MS/MS 









Thank you for these questions which highlight the 
importance of a good clinical history in poisoning 
cases. We asked whether the caregivers attempted 
treating the poisoning cases. This is referred to in 
the text that reads: 
 
“Six of the patients had vomiting induced by the care 
giver in an attempt to decontaminate.” 
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substances, or in case of 
multiple drugs detected, 
were part of a normal 
therapy or were 
administered by the 























“Of the 49 that had gastrointestinal symptoms 24 
(49%) had the presence of the confounder of 
intentional induction of vomiting by the caregivers 
using manual induction, milk and/or saltwater.” 
 
We also assessed for therapeutic drugs given at 
home or in hospital and even if these were identified 
by LC-MS/MS, they were not included in the analysis 
as cases of intoxication but classified as iatrogenic.  
As such, we believe that the multiple drugs 
identified by LC-MS/MS constitute true cases of 
multiple drug ingestions. 
 
This is demonstrated in the text that reads: 
 
“Altogether, in 89/152 (59%) participants a 
substance was detected. In 16 (18%) of these the 
detected substances were iatrogenic secondary to 
administration of in-hospital care or therapy given at 
home. After discounting the iatrogenic substances or 
medicines given at home 73 of 152 (48%, 95% CI 40 
– 56%) participants had a substance detected by LC-
MS/MS.” 
11.  Line 
225 
Is there any correlation 
between the source of 
isolation (blood/urine) and 
the test being positive or 
not? Did you consider the 
time after ingestion and 
the half-life of these drugs? 

























Thank you for this comment. As previously 
mentioned (and now clarified in the manuscript), the 
testing of a blood sample was of secondary concern. 
It was however precisely for the reason stated in this 
comment that we embarked on this opportunistic 
pursuit. We wanted to know if there is any 
discrepancies  between two different samples from 
the same individuals as would indicate value of 
metabolites that may have been excreted in urine 
that may aid identification of substances even when 
these are no longer detectable in blood. However 
since this was a secondary aim, the study was not 
powered to make formal correlations and we have 
refrained from claiming such in our discussion 
despite the noted higher yield in urine. We address 
our findings in a text that reads: 
 
“Seventy-four (74) patients had both urine and 
blood samples analysed on LC-MS/MS. Urine and 
blood LC-MS/MS yielded the exact same result in 48 
(65%) patients (table 4).  In 18(25%) of the 
participants with paired samples, more substances 
were detected in urine but not in blood, while in 4 
(5%) samples, more substances were detected in 











blood but not urine.”  
 
 
We have highlighted the value of this in our 
discussion in a section that reads, 
 
“While, both blood and urine samples can be 
analysed by LCMSMS, urine is usually readily 
available as a non-invasive specimen with minimal 
discomfort to children. Furthermore, unlike in blood, 
drugs  and their metabolites are known to remain in 
urine for longer (up to one week) post last exposure 
depending on the drug.(20, 21, 40) This gives a 
greater window of opportunity to still identify a 
substance after ingestion, especially when this is 
unknown or occult.” 
 
An attempt was made to collect information on time 
of ingestion but because in a significant number of 
cases the time of ingestion was not known partly 
because the poisoning was occult.  
12.  Fig 2 In figure 2 each data is 
detailed twice (in addition 
to the graph) and data are 




We apologise for this, thank you, we have removed 
the redundant data legend to get rid of the 
redundancy 
13  Is there a correlation 
among the poisoning 
substance detected in case 
of occult poisoning and the 
clinical presentation? have 
you assessed whether the 
intoxicant revealed by the 
LC-MS/MS is likely to be 





















Thank you for these questions which speak to clinical 
correlation with the substance identified. We have 
added the information and the text now reads: 
 
“In the 22(92%) cases of occult poisoning, in which 
LC-MS/MS identified a substance, the substance 
identified was in keeping with the clinical 
presentation in 20/22 (91%). The 2 patients, in 
whom LC-MS/MS identified a substance not in 
keeping with the clinical presentation, concomitant 
organophosphate poisoning was identified by 
alternative means. In these 2 organophosphate 
cases LC-MS/MS identified a substance that would 
have otherwise been missed.” 
 
We have also added the information on whether the 
substance revealed by LC-MS/Ms is responsible for 
the symptoms. The text now reads: 
 
“Of the 71 positive LC-MS/MS results in the 
substance-intake-likely group, the substances 
identified by LC-MS/MS were in keeping with the 
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clinical presentation in 55/71 (77%) participants. 
Nine (13%) of the 71 positive LC-MS/MS cases in the 
substance- likely-group were asymptomatic even 
though a substance was detected by LC-MS/MS.”  




We apologize this was an error when the graph was 
being formatted, that has been rectified. Thank you 
for noting the error. 
DISCUSSION 
14.  I'm not convinced by the 
first sentence "Our study 
illustrates the value of LC-
MS/MS in a LMIC setting, 
particularly in occult 
poisoning and in identifying 
multiple toxin ingestion." 
This statement would be 
more acceptable if a 
correlation between the 
substances found and the 
clinic were demonstrated. 
the work does not offer 
any data to show that the 
substance identified by LC-
MS/MS is really responsible 



































Thank you for the comment. In line with your advice, 
we have modified the opening sentence and added 
the section explaining correlation between clinical 
presentation. The texts now read: 
 
“Our study describes the prevalence of LC-MS/MS-
confirmed paediatric poisoning in a LMIC setting. LC-
MS/MS was particularly helpful in occult poisoning 
where it was able to identify over 90% of 
substances, as well as in identifying multiple 
substance ingestion.” 
 
“In the 22(92%) cases of occult poisoning, in which 
LC-MS/MS identified a substance, the substance 
identified was in keeping with the clinical 
presentation in 20/22 (91%). The 2 patients, in 
whom LC-MS/MS identified a substance not in 
keeping with the clinical presentation, concomitant 
organophosphate poisoning was identified by 
alternative means. In these 2 organophosphate 
cases LC-MS/MS identified a substance that would 
have otherwise been missed.” 
 
 
“Of the 71 positive LC-MS/MS results in the 
substance-intake-likely group, the substances 
identified by LC-MS/MS were in keeping with the 
clinical presentation in 55/71 (77%) participants. 
Nine (13%) of the 71 positive LC-MS/MS cases in the 
substance- likely-group were asymptomatic even 
though a substance was detected by LC-MS/MS.” 
 
Pertaining to multiple drugs identified we have 
indicated that we removed any drugs given in 
hospital or at home from the analysis. Such that 
multiple drugs identified were truly multiple drugs. 
The text reads: 
 
“Altogether, in 89/152 (59%) participants a 
substance was detected. In 16 (18%) of these the 
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detected substances were iatrogenic secondary to 
administration of in-hospital care or therapy given at 
home. After discounting the iatrogenic substances or 
medicines given at home 73 of 152 (48%, 95% CI 40 
– 56%) participants had a substance detected by LC-
MS/MS.” 
15.  Line 
329: 
"Twenty-six patients in this 
study ingested a substance 
that was not in the library, 
this was the main reason 
for a negative LC-MS/MS 
result in poisoning cases". 
I'm not convinced, the tests 
could be negative because 
they were done in the 
wrong time frame, or they 
could have revealed a 
substance that is not really 
responsible for the 
intoxication. The work as it 
is does not provide the 
useful elements to exclude 
















Page 21 , 
line 368 -
389 
Thank you for this comment - we acknowledge this 
as a limitation and have incorporated your 
suggestion into the discussion. We have added the 
other possibilities for a negative result and more 
information on the substance identified being 
responsible for the clinical presentation.  However, 
for these 26 whose reported ingested substances 
were not identified by LC-MS/MS in our study, 
specifically  for them, it means absence from the 
library of these substances implies even if the 
substance was present in the sample in whatever 
quantities, it could not have been detected. 
Consequently, we find our conclusion that, “This 
indicates that the ability of LC-MS/MS to detect a 
substance is limited by the extent of the LC-MS/MS 
library available at the time.”, inescapable.  
 
The text now reads: 
 
“Twenty-six patients in this study reported ingesting 
a substance that was not in the library. This was the 
main reason for a negative LC-MS/MS result in 
poisoning cases, in this study. This indicates that the 
ability of LC-MS/MS to detect a substance is limited 
by the extent of the LC-MS/MS library available at 
the time. Notably, the LC-MS/MS library can be 
updated and additional drugs/substances added.(18, 
19, 21) The LC-MS/MS used in this study could 
detect the presence of various drugs in 
concentrations as  low as 20ng/ml. Despite this high 
sensitivity, nine poisoning cases who had ingested 
drugs in the LC-MS/MS library were not detected. 
The possible explanations are varied and include, 
that the concentration of these drugs in the 
analysed samples may have been below the limit of 
detection of the instrument, either due to rapid 
metabolism or elimination. Six of the nine patients 
had vomiting induced by the care givers which could 
have led to decontamination, before the patient 
could absorb the drug. Notably, two of these 
patients were given activated charcoal. Worryingly, 
the first was a tricyclic antidepressant overdose, that 




LC-MS/MS did not detect. The second was a 
symptomatic chlorpromazine ingestion. This 
ingestion was witnessed, and the patient was given 
activated charcoal before the LC-MS/MS was done. 
It is possible that LC-MS/MS may have been limited 
by failure to detect substances that are eliminated 
via the hepatobiliary system which may not have 
been detectable in urine, as well as substances with 
a short half-life that may have degraded before 
sampling or analysis. These reasons are limitations of 
LC-MS/MS that the clinician needs to be aware of 
when utilising LC-MS/MS. All nine drugs that the LC-
MS/MS failed to identify, and yet were in the LC-
MS/MS library, are excreted in urine except for 
tenofovir, which is mainly excreted in faeces. A study 
done on sample stability indicated that substance 
degradation was dependent upon the type of 
substance and the temperature at which a sample is 
stored.” 





 "it is important to note 
that the clinical outcome 
was not altered using LC-
MS/MS, this corresponds 
to previous studies, and in 












Thank you for the comment, we have reworded the 
sentence to bring some clarity to this section. The 
statement we made only pertains to acute care as 
the results show that LC-MS/MS had an impact on 
considerations of child protection interventions as 
described. 
 
The text now reads: 
 
“It is important to note that the clinical outcome was 
not altered using LC-MS/MS, this corresponds to 
previous studies, and in our study was because of 
the long turnaround time, with a median of 5 ( IQR 3 
– 7) days  for urine LC-MS/MS and 6 (IQR 4 -7) days 
for blood.(19, 21). In our study, the turnaround time 
was prolonged because the test samples were 
batched” 




Reviewer 2 Comments 
 
Corrected/Revised dissertation 
1.  This study understandably is focused 
only on drug poisonings and without 
consideration of non-drug poisoning.   
Thank you, yes that is the main focus of the 
study. 
2.  As a Toxicologist, I will prefer the choice 
of toxic substance rather than toxin 
which skews more to substances of 
natural origin rather than synthetic 
substances like drugs.  
Thank you for this valuable point we have 
changed the terminology from ‘toxin’ to 
‘substance’ throughout the paper. 
 Some expressions may have to be 
referenced by the authors eg:  
  
3.  Page 7, line 
143-145 
Page 7, line 143-145 
















Thank you for the comment and request for 
reference. We opted not to group the cases 
as poisoning-likely, poisoning unclear and 
poisoning-unlikely, since the term poisoning 
would assume patient is symptomatic, 
whereas some patients ingested a substance 
but were not poisoned by it. 
 
We have added a reference explaining why 
we chose the terminology, and the text now 
reads: 
 
“As poisoning is defined  by the presence of 
clinical (somatic and/or mental) 
manifestations, or laboratory and/or 
electrocardiographic abnormalities resulting 
from exposure to a substance that can lead 
to harmful clinical effects (31), once all the 
toxicology investigations and clinical 
presentations were analysed, the authors 
classified  the cases into one of three groups: 
substance-intake-unlikely, substance-intake-
likely or substance-intake- unclear. The 
substance-intake-unlikely group were 
patients whose clinical presentation could be 
explained by an alternative medical diagnosis 
and were, therefore, not considered 
poisoning cases even though they were 
admitted as cases of suspected poisoning. 
The substance-intake-unclear group were 
patients whose clinical presentation could 
not be explained by a medical diagnosis and 
whose toxicology investigation results were 
not indicative of poisoning. The substance-
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intake-likely group were those patients 
whose clinical presentation could be 
explained by a toxic substance (even in the 
absence of an LC-MS/MS identified 
substance) and were therefore considered 
poisoning cases, even in the absence of 
symptoms.”  
4.  Lines 153-156 lines 153-156 should 
be referenced except 










Thank you for your comment. This was done 
for the purposes of the study and was the 
original idea of the authors. We have clarified 
that and the text now reads: 
 
“Irrespective of laboratory results, for the 
purposes of our study ,poisoning cases were 
also clinically divided by the authors into 
three groups: substance known (history of 
exposure to a known substance), toxin 
substance unknown (history of exposure to 
an unknown substance) and occult poisoning 
(no history of poisoning, but clinical 
presentation in keeping with poisoning).” 
5.  Reference 
section 
  The whole reference section has been 
revised with the addition of DOI numbers in 
line with the journal’s instructions to authors 
 
PI signature: _Heloise Buys____ __ Date: __16. December 2020___________ 
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Appendix I: Post-rebuttal BMC Pediatrics journal reviewer comments  
BPED-D-20-01221R1 
The prevalence of liquid chromatography-tandem mass spectrometry-confirmed paediatric 
poisoning at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa 
Norbertta Washaya, MBChB, FCPaed; Alicia Evans; Rudzani Muloiwa; Peter Smith; Heloise Buys 
BMC Pediatrics 
 
Dear Dr Buys, 
 
Your manuscript "The prevalence of liquid chromatography-tandem mass spectrometry-
confirmed paediatric poisoning at Red Cross War Memorial Children’s Hospital, Cape Town, South 
Africa" (BPED-D-20-01221R1) has been assessed by our reviewers. Based on these reports, and 
my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for 
publication in BMC Pediatrics, once you have carried out some essential revisions listed below. 
_________________________ 
 
1. Please upload the abstract as part of the main manuscript file. 
 
2. Please confirm whether informed consent obtained from all participants was written or verbal, 
and clearly state this in your Ethics approval and consent to participate section. If verbal, please 
state the reason and whether the ethics committee approved this procedure. 
 
3. At this stage, please upload your manuscript as a single, clean version that does not contain 
any tracked changes, comments, highlights, strikethroughs or text in different colours. All 
relevant tables/figures/additional files should also be clean versions. Figures (and additional files) 




Reviewer 1: the authors have responded satisfactorily to all the observations that have been 
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Appendix J: Acceptance letter from BMC Pediatrics journal 
 
BPED-D-20-01221R2 
The prevalence of liquid chromatography-tandem mass spectrometry-confirmed paediatric 
poisoning at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa 
Norbertta Washaya, MBChB, FCPaed; Alicia Evans; Rudzani Muloiwa; Peter Smith; Heloise Buys 
BMC Pediatrics 
 
Dear Dr Buys, 
 
I am pleased to inform you that your manuscript "The prevalence of liquid chromatography-
tandem mass spectrometry-confirmed paediatric poisoning at Red Cross War Memorial Children’s 
Hospital, Cape Town, South Africa" (BPED-D-20-01221R2) has been accepted for publication in 
BMC Pediatrics. 
 
If any final comments have been submitted from our reviewers or editors, these can be found at 
the foot of this email for your consideration. 
 
Before publication, our production team will also check the format of your manuscript to ensure 
that it conforms to the standards of the journal. They will be in touch shortly to request any 
necessary changes, or to confirm that none are needed. 
 
Articles in this journal may be held for a short period of time prior to publication. 
If you have any concerns please contact the journal. 
 
Please do not hesitate to contact us if you have any questions regarding your manuscript and I 
hope that you will consider BMC Pediatrics again in the future. 
 
If you wish to co-submit a data note to be published in BMC Research Notes 
(https://bmcresnotes.biomedcentral.com/about/introducing-data-notes) you can do so by visiting 
our submission portal http://www.editorialmanager.com/resn/. Data notes support open data 
(https://www.springernature.com/gp/open-research/open-data) and help authors to comply with 
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present a title that includes, if appropriate, the study design e.g.:
"A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for Y: a case
control study", "What is the impact of factor X on subject Y: A systematic review"
or for non-clinical or non-research studies a description of what the article reports
list the full names and institutional addresses for all authors 
Appendix L: Author Guidelines BMC Pediatrics Journal
Research article
Criteria
Research articles should report on original primary research, but may report on systematic reviews of published 
research provided they adhere to the appropriate reporting guidelines which are detailed in our editorial policies. 
Please note that non-commissioned pooled analyses of selected published research will not be considered. Studies 
reporting descriptive results from a single institution will only be considered if analogous data have not been 
previously published in a peer reviewed journal and the conclusions provide distinct insights that are of relevance 
to a regional or international audience.
BMC Pediatrics strongly encourages that all datasets on which the conclusions of the paper rely should be available 
to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories 
(where available and appropriate) or presented in the main manuscript or additional supporting files whenever 
possible. Please see Springer Nature’s information on recommended repositories. Where a widely established 
research community expectation for data archiving in public repositories exists, submission to a community-
endorsed, public repository is mandatory. A list of data where deposition is required, with the appropriate 
repositories, can be found on the Editorial Policies Page.
Preparing your manuscript
The information below details the section headings that you should include in your manuscript and what 
information should be within each section.
Please note that your manuscript must include a 'Declarations' section including all of the subheadings (please see 
below for more information).
Title page
The title page should:
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if a collaboration group should be listed as an author, please list the Group name as an author. If you
would like the names of the individual members of the Group to be searchable through their individual
PubMed records, please include this information in the “Acknowledgements” section in accordance
with the instructions below
indicate the corresponding author
Abstract
The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not cite references in
the abstract. Reports of randomized controlled trials should follow the CONSORT extension for abstracts. The
abstract must include the following separate sections:
Background: the context and purpose of the study
Methods: how the study was performed and statistical tests used
Results: the main findings
Conclusions: brief summary and potential implications
Trial registration: If your article reports the results of a health care intervention on human participants, it
must be registered in an appropriate registry and the registration number and date of registration should be in
stated in this section. If it was not registered prospectively (before enrollment of the first participant), you
should include the words 'retrospectively registered'. See our editorial policies for more information on trial
registration
Keywords
Three to ten keywords representing the main content of the article.
Background
The Background section should explain the background to the study, its aims, a summary of the existing literature
and why this study was necessary or its contribution to the field.
Methods
The methods section should include:
the aim, design and setting of the study
the characteristics of participants or description of materials
a clear description of all processes, interventions and comparisons. Generic drug names should generally be
used. When proprietary brands are used in research, include the brand names in parentheses
the type of statistical analysis used, including a power calculation if appropriate
Results
This should include the findings of the study including, if appropriate, results of statistical analysis which must be
included either in the text or as tables and figures.
Discussion
This section should discuss the implications of the findings in context of existing research and highlight limitations
of the study.
Conclusions
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This should state clearly the main conclusions and provide an explanation of the importance and relevance of the
study reported.
List of abbreviations
If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations should
be provided. 
Declarations
All manuscripts must contain the following sections under the heading 'Declarations':
Ethics approval and consent to participate
Consent for publication






Please see below for details on the information to be included in these sections.
If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for
that section. 
Ethics approval and consent to participate
Manuscripts reporting studies involving human participants, human data or human tissue must:
include a statement on ethics approval and consent (even where the need for approval was waived)
include the name of the ethics committee that approved the study and the committee’s reference number if
appropriate
Studies involving animals must include a statement on ethics approval and for experimental studies involving
client-owned animals, authors must also include a statement on informed consent from the client or owner.
See our editorial policies for more information.
If your manuscript does not report on or involve the use of any animal or human data or tissue, please state “Not
applicable” in this section.
Consent for publication
If your manuscript contains any individual person’s data in any form (including any individual details, images or
videos), consent for publication must be obtained from that person, or in the case of children, their parent or legal
guardian. All presentations of case reports must have consent for publication.
You can use your institutional consent form or our consent form if you prefer. You should not send the form to us
on submission, but we may request to see a copy at any stage (including after publication).
See our editorial policies for more information on consent for publication.
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If your manuscript does not contain data from any individual person, please state “Not applicable” in this section.
Availability of data and materials
All manuscripts must include an ‘Availability of data and materials’ statement. Data availability statements should
include information on where data supporting the results reported in the article can be found including, where
applicable, hyperlinks to publicly archived datasets analysed or generated during the study. By data we mean the
minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article.
We recognise it is not always possible to share research data publicly, for instance when individual privacy could be
compromised, and in such instances data availability should still be stated in the manuscript along with any
conditions for access.
Data availability statements can take one of the following forms (or a combination of more than one if required for
multiple datasets):
The datasets generated and/or analysed during the current study are available in the [NAME] repository,
[PERSISTENT WEB LINK TO DATASETS]
The datasets used and/or analysed during the current study are available from the corresponding author on
reasonable request.
All data generated or analysed during this study are included in this published article [and its supplementary
information files].
The datasets generated and/or analysed during the current study are not publicly available due [REASON
WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
Data sharing is not applicable to this article as no datasets were generated or analysed during the current
study.
The data that support the findings of this study are available from [third party name] but restrictions apply to
the availability of these data, which were used under license for the current study, and so are not publicly
available. Data are however available from the authors upon reasonable request and with permission of [third
party name].
Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in this section.
More examples of template data availability statements, which include examples of openly available and restricted
access datasets, are available here.
BioMed Central also requires that authors cite any publicly available data on which the conclusions of the paper
rely in the manuscript. Data citations should include a persistent identifier (such as a DOI) and should ideally be
included in the reference list. Citations of datasets, when they appear in the reference list, should include the
minimum information recommended by DataCite and follow journal style. Dataset identifiers including DOIs
should be expressed as full URLs. For example:
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring and prediction system
(GIDMaPS) data sets. figshare. 2014. http://dx.doi.org/10.6084/m9.figshare.853801
With the corresponding text in the Availability of data and materials statement:
The datasets generated during and/or analysed during the current study are available in the [NAME] repository,
[PERSISTENT WEB LINK TO DATASETS].[Reference number] 
If you wish to co-submit a data note describing your data to be published in BMC Research Notes, you can do so by
visiting our submission portal. Data notes support open data and help authors to comply with funder policies on
data sharing. Co-published data notes will be linked to the research article the data support (example).
For more information please email our Research Data Team.
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You may choose to use this section to include any relevant information about the author(s) that may aid the reader's
interpretation of the article, and understand the standpoint of the author(s). This may include details about the
authors' qualifications, current positions they hold at institutions or societies, or any other relevant background
information. Please refer to authors using their initials. Note this section should not be used to describe any
competing interests.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the
reference list. They should not consist solely of a reference citation, and they should never include the
bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case
letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the
article are not given reference symbols.
Always use footnotes instead of endnotes.
References
Examples of the Vancouver reference style are shown below.
See our editorial policies for author guidance on good citation practice
Web links and URLs: All web links and URLs, including links to the authors' own websites, should be given a
reference number and included in the reference list rather than within the text of the manuscript. They should be
provided in full, including both the title of the site and the URL, as well as the date the site was accessed, in the
following format: The Mouse Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed
20 May 2013. If an author or group of authors can clearly be associated with a web link, such as for weblogs, then
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Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat
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Article within a journal by DOI
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 2000;
doi:10.1007/s801090000086.
Article within a journal supplement
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone marrow scan.
Blood 1979;59 Suppl 1:26-32.
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 Preparing main manuscript text
 Preparing illustrations and figures
 Preparing tables 
 Preparing additional files
Preparing figures
Back to top
When preparing figures, please follow the formatting instructions below.
Figures should be numbered in the order they are first mentioned in the text, and uploaded in this
order. Multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a single composite file that
contains all parts of the figure.
Figures should be uploaded in the correct orientation.
Figure titles (max 15 words) and legends (max 300 words) should be provided in the main manuscript, not in
the graphic file.
Figure keys should be incorporated into the graphic, not into the legend of the figure.
Each figure should be closely cropped to minimize the amount of white space surrounding the illustration.
Cropping figures improves accuracy when placing the figure in combination with other elements when the
accepted manuscript is prepared for publication on our site. For more information on individual figure file
formats, see our detailed instructions.
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Individual figure files should not exceed 10 MB. If a suitable format is chosen, this file size is adequate for
extremely high quality figures.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder
to reproduce figures (or tables) that have previously been published elsewhere. In order for all figures to
be open access, authors must have permission from the rights holder if they wish to include images that have
been published elsewhere in non open access journals. Permission should be indicated in the figure legend,
and the original source included in the reference list.
Figure file types
We accept the following file formats for figures:
EPS (suitable for diagrams and/or images)
PDF (suitable for diagrams and/or images)
Microsoft Word (suitable for diagrams and/or images, figures must be a single page)
PowerPoint (suitable for diagrams and/or images, figures must be a single page)
TIFF (suitable for images)
JPEG (suitable for photographic images, less suitable for graphical images)
PNG (suitable for images)
BMP (suitable for images)
CDX (ChemDraw - suitable for molecular structures)
For information and suggestions of suitable file formats for specific figure types, please see our author academy.
Figure size and resolution
Figures are resized during publication of the final full text and PDF versions to conform to the BioMed Central
standard dimensions, which are detailed below.
Figures on the web:
width of 600 pixels (standard), 1200 pixels (high resolution).
Figures in the final PDF version:
width of 85 mm for half page width figure
width of 170 mm for full page width figure
maximum height of 225 mm for figure and legend
image resolution of approximately 300 dpi (dots per inch) at the final size
Figures should be designed such that all information, including text, is legible at these dimensions. All lines should
be wider than 0.25 pt when constrained to standard figure widths. All fonts must be embedded.
Figure file compression
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Vector figures should if possible be submitted as PDF files, which are usually more compact than EPS files.
TIFF files should be saved with LZW compression, which is lossless (decreases file size without decreasing
quality) in order to minimize upload time.
JPEG files should be saved at maximum quality.
Conversion of images between file types (especially lossy formats such as JPEG) should be kept to a
minimum to avoid degradation of quality.
If you have any questions or are experiencing a problem with figures, please contact the customer service team at
info@biomedcentral.com.
Preparing main manuscript text
Back to top
Quick points:
Use double line spacing
Include line and page numbering
Use SI units: Please ensure that all special characters used are embedded in the text, otherwise they will be
lost during conversion to PDF
Do not use page breaks in your manuscript
File formats
The following word processor file formats are acceptable for the main manuscript document:
Microsoft word (DOC, DOCX)
Rich text format (RTF)
TeX/LaTeX (use BioMed Central's TeX template)
Please note: editable files are required for processing in production. If your manuscript contains any non-editable
files (such as PDFs) you will be required to re-submit an editable file when you submit your revised manuscript, or
after editorial acceptance in case no revision is necessary.
Additional information for TeX/LaTeX users
Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX format. Submit your references
using either a bib or bbl file. When submitting TeX submissions, please submit both your TeX file and your bib/bbl
file as manuscript files. Please also convert your TeX file into a PDF (please do not use a DIV file) and submit this
PDF as a supplementary file with the name 'Reference PDF'. This PDF will be used by our production team as a
reference point to check the layout of the article as the author intended. 
The Editorial Manager system checks for any errors in the Tex files. If an error is present then the system PDF will
display LaTex code and highlight and explain the error in a section beginning with an exclamation mark (!).
All relevant editable source files must be uploaded during the submission process. Failing to submit these source
files will cause unnecessary delays in the production process.
TeX templates
29/12/2020 BMC Pediatrics | Preparing your manuscript
https://bmcpediatr.biomedcentral.com/submission-guidelines/preparing-your-manuscript 5/11
BioMedCentral_article (ZIP format) - preferred template
article (part of the standard TeX distribution)
amsart (part of the standard TeX distribution)
Style and language
For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the
English language is of sufficient quality to be understood. If you need help with writing in English you should
consider:
Visiting the English language tutorial which covers the common mistakes when writing in English.
Asking a colleague who is a native English speaker to review your manuscript for clarity.
Using a professional language editing service where editors will improve the English to ensure that your
meaning is clear and identify problems that require your review. Two such services are provided by our
affiliates Nature Research Editing Service and American Journal Experts. BMC authors are entitled to a 10%
discount on their first submission to either of these services. To claim 10% off English editing from Nature
Research Editing Service, click here. To claim 10% off American Journal Experts, click here.
Please note that the use of a language editing service is not a requirement for publication in the journal and does not






核的问题。例如我们的附属机构 Nature Research Editing Service 以及合作伙伴 American Journal
Experts 都可以提供此类专业服务。BMC作者享受首次订单10%优惠，该优惠同时适用于两家公司。
您只需点击以下链接即可开始。使用 Nature Research Editing Service的编辑润色10%的优惠服务，请
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プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英
語を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携し
ているサービスです。BMCのジャーナルの著者は、いずれかのサービスを初めて利用する際に、
10%の割引を受けることができます。Nature Research Editing Serviceの10%割引を受けるには、こち




영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이
충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신
다면 다음의 사항들을 고려하여 주십시오:
영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다
리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수
준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service와 American
Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. BMC에서는 위의 두 가지의 서
비스를 첫 논문 투고를 위해 사용하시는 경우, 10%의 할인을 제공하고 있습니다. Nature Research
Editing Service이용시 10% 할인을 요청하기 위해서는 여기를 클릭해 주시고, American Journal Experts
이용시 10% 할인을 요청하기 위해서는 여기를 클릭해 주십시오.
영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거
나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.
  
Data and materials
For all journals, BioMed Central strongly encourages all datasets on which the conclusions of the manuscript rely
to be either deposited in publicly available repositories (where available and appropriate) or presented in the main
paper or additional supporting files, in machine-readable format (such as spread sheets rather than PDFs) whenever
possible. Please see the list of recommended repositories in our editorial policies.
For some journals, deposition of the data on which the conclusions of the manuscript rely is an absolute
requirement. Please check the Instructions for Authors for the relevant journal and article type for journal specific
policies.
For all manuscripts, information about data availability should be detailed in an ‘Availability of data and materials’
section. For more information on the content of this section, please see the Declarations section of the relevant
journal’s Instruction for Authors. For more information on BioMed Centrals policies on data availability, please see
our [editorial policies].
Formatting the 'Availability of data and materials' section of your manuscript
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The following format for the 'Availability of data and materials section of your manuscript should be used:
"The dataset(s) supporting the conclusions of this article is(are) available in the [repository name] repository,
[unique persistent identifier and hyperlink to dataset(s) in http:// format]."
The following format is required when data are included as additional files:
"The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional
file(s))."
BioMed Central endorses the Force 11 Data Citation Principles and requires that all publicly available datasets be
fully referenced in the reference list with an accession number or unique identifier such as a DOI.
For databases, this section should state the web/ftp address at which the database is available and any restrictions to
its use by non-academics.
For software, this section should include:
Project name: e.g. My bioinformatics project
Project home page: e.g. http://sourceforge.net/projects/mged
Archived version: DOI or unique identifier of archived software or code in repository (e.g. enodo)
Operating system(s): e.g. Platform independent
Programming language: e.g. Java
Other requirements: e.g. Java 1.3.1 or higher, Tomcat 4.0 or higher
License: e.g. GNU GPL, FreeBSD etc.
Any restrictions to use by non-academics: e.g. licence needed
Information on available repositories for other types of scientific data, including clinical data, can be found in our
editorial policies.
References
See our editorial policies for author guidance on good citation practice.
Please check the submission guidelines for the relevant journal and article type. 
What should be cited?
Only articles, clinical trial registration records and abstracts that have been published or are in press, or are
available through public e-print/preprint servers, may be cited.
Unpublished abstracts, unpublished data and personal communications should not be included in the reference list,
but may be included in the text and referred to as "unpublished observations" or "personal communications" giving
the names of the involved researchers. Obtaining permission to quote personal communications and unpublished
data from the cited colleagues is the responsibility of the author. Only footnotes are permitted. Journal
abbreviations follow Index Medicus/MEDLINE.
Any in press articles cited within the references and necessary for the reviewers' assessment of the manuscript
should be made available if requested by the editorial office.
How to format your references
Please check the Instructions for Authors for the relevant journal and article type for examples of the relevant
reference style.
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Web links and URLs: All web links and URLs, including links to the authors' own websites, should be given a
reference number and included in the reference list rather than within the text of the manuscript. They should be
provided in full, including both the title of the site and the URL, as well as the date the site was accessed, in the
following format: The Mouse Tumor Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed
20 May 2013. If an author or group of authors can clearly be associated with a web link, such as for weblogs, then
they should be included in the reference.




When preparing tables, please follow the formatting instructions below.
Tables should be numbered and cited in the text in sequence using Arabic numerals (i.e. Table 1, Table 2
etc.).
Tables less than one A4 or Letter page in length can be placed in the appropriate location within the
manuscript.
Tables larger than one A4 or Letter page in length can be placed at the end of the document text file. Please
cite and indicate where the table should appear at the relevant location in the text file so that the table can be
added in the correct place during production.
Larger datasets, or tables too wide for A4 or Letter landscape page can be uploaded as additional files. Please
see [below] for more information.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma separated
values (.csv). Please use the standard file extensions.
Table titles (max 15 words) should be included above the table, and legends (max 300 words) should be
included underneath the table.
Tables should not be embedded as figures or spreadsheet files, but should be formatted using ‘Table object’
function in your word processing program.
Color and shading may not be used. Parts of the table can be highlighted using superscript, numbering,
lettering, symbols or bold text, the meaning of which should be explained in a table legend.
Commas should not be used to indicate numerical values.




As the length and quantity of data is not restricted for many article types, authors can provide datasets, tables,
movies, or other information as additional files.
All Additional files will be published along with the accepted article. Do not include files such as patient consent
forms, certificates of language editing, or revised versions of the main manuscript document with tracked changes.
Such files, if requested, should be sent by email to the journal’s editorial email address, quoting the manuscript
reference number. Please do not send completed patient consent forms unless requested.
Results that would otherwise be indicated as "data not shown" should be included as additional files. Since many
web links and URLs rapidly become broken, BioMed Central requires that supporting data are included as
additional files, or deposited in a recognized repository. Please do not link to data on a personal/departmental
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website. Do not include any individual participant details. The maximum file size for additional files is 20 MB
each, and files will be virus-scanned on submission. Each additional file should be cited in sequence within the
main body of text.
If additional material is provided, please list the following information in a separate section of the manuscript text:
File name (e.g. Additional file 1)
File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL
of an appropriate viewer if format is unusual)
Title of data
Description of data
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name
within the body of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'.
For further guidance on how to use Additional files or recommendations on how to present particular types of data
or information, please see How to use additional files.
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